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Next-Generation Sequencing (NGS) technologies enabled the 
characterization of the human genome and its variation in great detail within 
large cohorts. The current medical research aims towards personalized 
medicine, whereby identifying the causal disease mechanisms in each 
individual will promote more tailored forms of treatment. Rare diseases have 
been in the front line of the individual-level molecular diagnoses, resulting 
from their typical monogenic inheritance. NGS technologies made it possible 
to solve cases that were a challenge to traditional methods, either imposed by 
their extreme rarity or by the genetic heterogeneity of the disorders. In 
genetic studies, NGS technologies involve targeted sequencing panels of 
known disease genes, whole-exome sequencing (WES) covering the genome's 
protein-coding part, and whole-genome sequencing (WGS). Our study 
applied targeted panels and WES for the genetic diagnosis of severe 
childhood disorders, starting with a progressive neurological syndrome and 
continuing with a cohort of 66 children diagnosed with cardiomyopathy, a 
leading cause of pediatric heart transplants. 
First, we focused on genetic leukoencephalopathies, a heterogeneous 
group of central nervous system disorders with white matter involvement. 
We studied a Finnish patient presenting genetic hypomyelinating 
leukoencephalopathy with atrophy of the cerebellar vermis. WES identified a 
novel homozygous mutation in HIKESHI. Hikeshi binds and carries the 
molecular chaperones HSP70s into the nucleus in response to heat shock. A 
founder Ashkenazi-Jewish mutation previously linked Hikeshi and its heat 
shock protective function to leukoencephalopathy. Structural modeling of the 
amino acid changes and protein analyses revealed that modified interactions 
inside Hikeshi's hydrophobic pockets induce protein instability. The patient's 
cells showed impaired nuclear translocation of HSP70s during heat shock 
and decreased ERO1-Lα, an endoplasmic reticulum (ER) oxidoreductase. Our 
study was the second report of HIKESHI mutations, extended the phenotypic 
spectrum associated with Hikeshi disease, and showed that the cellular 
pathogenic process involves nuclear chaperone and ER functions. 
Second, we studied the genetics of childhood cardiomyopathies (CMPs), 
the most common cause of heart failure and the leading indication for a heart 
transplant in children. Cardiomyopathies can manifest as isolated heart 
disorders or as components of developmental and metabolic disorders. 
Despite severe courses, often leading to heart transplantation, childhood 
cardiomyopathies have been relatively understudied from a genetic 
perspective. To cover this knowledge gap, we collected a unique cohort of 66 
childhood-onset CMP patients (KidCMP) from the single center in Finland 
performing cardiac transplantations. Overall in the cohort, including six 
previously published findings, we uncovered the pathogenic variants in 39% 
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of patients: 46% de novo, 34% recessive, and 20% dominantly inherited. The 
disease genes converge on metabolic causes (PRKAG2, MRPL44, AARS2, 
HADHB, DNAJC19, PPA2, TAZ, BAG3), MAPK pathways (HRAS, PTPN11, 
RAF1, TAB2), development (NEK8, TBX20), calcium handling (JPH2, 
CALM1, CACNA1C), the sarcomeric function (TNNC1, TNNI3, ACTC1, 
MYH7), and the cytoskeleton (NRAP). We found that severe childhood 
cardiomyopathies are typically caused by rare pathogenic variants, 
commonly de novo, indicating that NGS of trios is the best approach in their 
diagnosis. Our study was the first countrywide genetic characterization of 
severe early-onset cardiomyopathies and indicated the importance of early 
diagnosis in treatment optimization. 
Third, we identified a recessive pathogenic variant in TMOD1 as a novel 
genetic cause for cardiomyopathy in three patients from two independent 
families. Tmod1 binds filamentous actin at its pointed, slow-growing end, 
controlling thin filament length in cardiomyocytes. The overexpression of 
mutant and wild type protein fused with GFP in U2OS (human 
osteosarcoma) cells suggested that the mutant is prone to form aggregates. In 
the patient muscle, however, the protein was at normal levels. We employed 
induced pluripotent stem cells derived cardiomyocytes (iPSC-CMs) for 
investigating the distribution of Tmod1 and related proteins in the patient 
and controls. We found only minor changes in the sarcomeric structure, 
challenging to interpret in the context of differentiation heterogeneity. 
Molecular modeling of patients' mutation showed that the variant 
determines a hydrophobic amino acid exposure at the protein's surface, 
which may influence the local folding and affinity for actin. Taken together 
with the cell-based studies, we suggest that the patient mutation likely alters 
thin filament's pointed end dynamics in cardiomyocytes. 
We made substantial progress in understanding the molecular basis of 
the studied disorders. First, we strengthen the evidence that heat shock 
response is a novel mechanism underlying leukoencephalopathy. Second, we 
characterized genetically a cohort of early-onset severe cardiomyopathies, 
representing the whole of Finland for patients evaluated for cardiac 
transplantation or receiving inotropic support. Third, we characterized a 
novel disease gene causing childhood cardiomyopathies, an important step in 
further deciphering the genetic landscape of these severe heart disorders. 
Altogether, this thesis highlights the power of novel technologies in 
identifying causal genetic variants and characterizing novel disease genes. 
Our findings enhance knowledge of the underlying molecular mechanisms 
and potentially aid in developing new therapeutic interventions. For families, 
the genetic diagnosis enables a causative recognition of the disease and 
identifying individuals at risk. Our cardiomyopathy project also contributed 
to establishing a protocol for systematic genetic testing of patients and 
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The human genome is built on a four-letter nucleotide language, which 
ultimately governs all aspects of cell functioning. With the aims of providing 
a genetic, physical, and sequence map of our genome, the Human Genome 
Project (HGP) was initiated in 1990, the first 'draft' published in 2001 
(Lander et al, 2001; Venter et al, 2001), and continued few more years 
afterward to finalize the 'essentially complete genome'. This 3.5-billion-
dollar, 13-year program was a substantial multicenter effort, which promoted 
significant technological and bioinformatic advancements. It also inoculated 
a culture of large-scale cooperation in research and introduced the concept of 
'big data' in biology (Hood and Rowen, 2013). The 'catalogs' of genes and 
proteins assembled by the HGP have been essential for the development of 
'systems biology' applications in biomedical sciences. HGP's societal echoes 
are enormously increasing, as they gradually include novel aspects, such as 
genetic privacy, potential discrimination, genetic determinism, or non-
determinism, and identity politics. 
The HGP inspired other large-scale projects in multiple biology 
disciplines, such as the Cancer Genome Atlas (The Cancer Genome Atlas 
Research Network et al, 2013), the Human Brain Project 
(www.humanbrainproject.eu), and the Human Proteome Project (Legrain et 
al, 2011). Following HGP, the description of human genetic variation was 
pioneered by the HapMap Project (International HapMap Consortium, 2005; 
International HapMap Consortium et al, 2007), which aimed to identify 
haplotype blocks of common single nucleotide polymorphisms (SNPs) in 
different populations. The 1000 Genomes Project followed (The 1000 
Genomes Project Consortium, 2010) and cataloged common and rare single-
nucleotide and structural variation in multiple populations. 
The data obtained in these large projects supported early clinical 
genome-wide association studies (GWAS), which correlate specific genetic 
variants with disease risk based on case-control comparisons. On the other 
hand, to identify rare, highly penetrant disease-causing variants, pedigree-
based whole-exome sequencing offers a more robust approach. The 
dichotomy of common variants-common disorders versus rare variants-rare 
disorders has been the basis for the technological split between the two 
genetic areas. Therefore, microchips versus exome-sequencing gradually 
hand over to whole-genome sequencing, which fundamentally aims to 
capture all genetic variation in a genome, common and rare, coding and 
noncoding. Presently, hundreds of thousands of individual genomes are 
sequenced worldwide to identify disease-causing variants or, more broadly, 
to establish associations between sequence variation and phenotypes 
(Claussnitzer et al, 2020). 
Introduction 
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It is foreseeable that, soon, individual genomes will play a larger role in 
medical practice. Individuals will use the genomic information to improve 
their health through prevention or therapeutic strategies appropriate for a 
condition indicated by their genome (Özdemir et al, 2017). The application of 
systems approaches to diseases shapes our understanding of how metabolic 
or cell signaling networks become perturbed in different diseased tissues and 
how they change as the disease progresses. Having a clear picture of how 
these molecular events unfold will provide novel approaches to diagnosis and 
treatments. Adding this layer of information to the knowledge of the 
individual genetic makeup, with its own risk and protective variants, will 
shape a predictive, preventive, personalized, and participatory medicine: P4 
medicine. 
Given the simpler genetic architecture of rare diseases, typically of 
monogenic origin, they are one of the immediate applications of P4 medicine. 
Moreover, it is easier to study and catalog one-gene perturbation effects in 
different models and tissues. Rare disorders have also been the front line of 
genetic investigation using Next-Generation Sequencing (NGS) approaches, 
with tremendous success in disease gene discovery over the last decade 
(Frésard and Montgomery, 2018). 
Despite this, it is estimated that about half of the causative genes 
involved in rare disorders are still to be identified (Bamshad et al, 2019; 
Chong et al, 2015). Many factors can contribute to this 'missing heritability', 
among them the rarity of different disorders, their genetic and phenotypic 
variability, the need for technological and bioinformatic advancements to 
capture all types of genome variation, along with overcoming current 
challenges in interpreting noncoding functional variation of the genome 
(Boycott et al, 2019). 
In this thesis, we used NGS technologies coupled with functional studies 
to advance the molecular characterization of rare childhood disorders in 
Finland, focusing on cardiomyopathy. Induced pluripotent stem cell disease 
modeling allowed us to explore the possibilities that are at the horizon for 
personalized approaches in rare disorders. 
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2. REVIEW OF THE LITERATURE 
2.1. STRUCTURE AND EXPRESSION OF THE HUMAN 
GENOME 
2.1.1. CHROMOSOMES AND 3D ORGANIZATION 
The DNA represents the genetic material containing all the information 
essential for life and the basis for heredity. The human genome comprises 46 
nuclear chromosomal DNA molecules (22 pairs of autosomes and two sex 
chromosomes XY) and a multicopy small circular mitochondrial genome 
(Strachan and Read, 2018). The DNA in the nucleus (nDNA) hosts most 
genes and contains >6 billion nucleotides that would measure ~2 m in length 
(Fraser et al, 2015). One circular copy of the mitochondrial genome (mtDNA) 
contains 16,569 base pairs and harbors only 37 intronless genes. MtDNA 
exists in multiple copies inside mitochondria, between 100 and 10,000 
molecules per cell, on a cell-type-specific basis (Gammage and Frezza, 2019). 
Exceptionally, oocytes present over 100,000 mtDNA copies that are 
distributed between daughter cells during initial embryonic cell divisions. 
The three-dimensional organization of the genome is crucial for both 
integrity maintenance and gene regulation. Because of extensive length and 
functional constraints, the nDNA is hierarchically folded to reach a 
compaction level estimated at ~10,000 fold for metaphase chromosomes 
(Grigoryev, 2018). 
During interphase, chromosomes exist as territories, defined by the 
nuclear space occupied by each chromosome, with a roughly ovoidal shape 
and 2-3 µm in diameter. Interphase chromosomes have irregular folding that 
implies a less constrained chromatin state, which allows the access of gene 
regulatory factors to the DNA. Adjacent territories may overlap considerably, 
and chromatin loops can reach out into neighboring territories (Fraser et al, 
2015). 
Within chromosome territories, there are two types of chromosome 
compartments: open A compartments associated with indices of active and 
poised chromatin (such as specific histone markers, high GC content, 
increase in DNaseI hypersensitivity sites); closed B compartments of silenced 
chromatin (such as silencing histone markers, tighter self-association, late 
replication timing) (Fraser et al, 2015; Lieberman-Aiden et al, 2009). 
A smaller-scale organization gives rise to topologically-associated 
domains (TADs). TADs form distinct globular, self-interacting units that are 
well delimitated spatially and contain genes that tend to be coexpressed 
(Dixon et al, 2012). Even finer structures emerge from the ability of the 
chromatin to fold into loops, promoting long-distance interactions. 
Review of literature 
15 
Chromatin looping has been the preferred model to explain the interaction 
between promoters and regulatory elements (Rao et al, 2014a). 
Nucleosomes represent the basic packaging level and contain octamers of 
core histone proteins and a DNA segment wrapping around them. 
Nucleosomes are separated by stretches of DNA, often occupied by linker 
histones. This structure is generally compared with beads-on-a-string and 
forms the classical ~10 nm chromatin fiber that provides 7-fold compaction 
of the DNA (Krumm and Duan, 2019). Recent studies suggested that, in 
interphase chromosomes, chromatin fibers are irregularly folded from both 
nucleosome-containing and nucleosome-depleted DNA stretches, resulting 
in fibers with diverse diameters (5 nm - 24 nm) and poorly described 
geometry in vivo (Ou et al, 2017). Metaphase chromosomes are at least 100 
fold more compacted than interphase chromosomes. This level of 
compaction in metaphase chromosomes is achieved by tightly packed 
consecutive chromatin loops of ~100 kb in length (Goloborodko et al, 2016). 
At whole nucleus resolution, the genome organization depends on 
contacts with different nuclear substructures. For example, laminin-
associated domains and nucleolus-associated domains frequently contain 
transcriptionally-inactive heterochromatin and are gene-poor. On the 
contrary, nuclear pores present in their vicinity 'heterochromatin exclusion 
zones', suggesting a possible coupling of transcription with nuclear export 
(Fraser et al, 2015). The 3D organization is largely similar in specific cell 
types. During development or cell differentiation, chromatin compartments 
undergo dynamic switches as cells transition between cell types (Zheng and 
Xie, 2019). Disruption of the 3D genome architecture can lead to disease, 
often by a pathogenic promoter-enhancer interaction (Lupiáñez et al, 2015, 
2015), which disrupts the normal gene expression. 
2.1.2. GENES, REGULATORY ELEMENTS, AND REPETITIVE 
SEQUENCES 
From human genetics point of view, much emphasis has been on identifying 
and characterizing the genome's genes because a large proportion of the 
variation involved in disease resides within genes. The genes are functional 
elements of the genome, consisting of transcribed DNA sequences that 
ultimately generate functional products: proteins, functional RNAs, or both. 
Analyses of the human reference genome (GRCh38) indicate that there 
are approximately 19,950-20,200 protein-coding genes. Nevertheless, the 
actual number of unique proteins increases by magnitudes using alternative 
start codons, alternative splicing of messenger RNA (mRNA), and post-
translational modifications of proteins. In many instances, these isoforms 
have different tissue specificities and functions (Boeckmann et al, 2005). For 
protein-coding genes, the mean exon size is 268 nucleotides (median 129), 
with an average of 9 exons per gene. If we exclude the first and last exons, 
typically long and mostly untranslated, the mean length of internal exons is 
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147 nucleotides (median 121). Introns vary enormously in size, from a few to 
over 100,000 nucleotides, with a small minority of genes lacking introns 
(Strachan and Read, 2018). Because transcription of long introns is costly (16 
hours to transcribe the 2.3 Mb dystrophin gene) (Tennyson et al, 1995), 
highly expressed genes tend to have short introns or are intronless (Castillo-
Davis et al, 2002). 
The human genome also contains RNA genes, which are much more 
diverse and far less characterized than protein-coding genes. RNA genes 
raise particular challenges related to their definition. Their identification is 
also challenging, often because they have been poorly conserved during 
evolution and they do not have open reading frames to facilitate searching 
(Kashi et al, 2016). By convention, RNA genes belong to two classes: short 
noncoding RNAs (sncRNAs), when their mature products are ≤200 
nucleotides, or long noncoding RNAs (lncRNAs) if >200 nucleotides. The 
200 nucleotide threshold promotes an arbitrary classification, which 
artificially separates the ribosomal RNAs into two classes (cytoplasmic 28S 
and 18S, mitochondrial 16S and 12S belong to lncRNAs, while cytoplasmic 
5.8S and 5S to sncRNA). Genes encoding lncRNAs can be tens of kilobases 
long and often contain introns, with an average of 1.8 transcripts per gene. 
The average length of exons of lncRNA genes is 683 nucleotides, with a 
median of 129 (Strachan and Read, 2018). On the other hand, the small RNA 
genes, like those that specify micro RNAs (miRNAs), are often intronless. 
However, small functional noncoding RNAs can arise even from processed 
introns after splicing, complicating the RNA gene definition. As a 
consequence of their diversity, the functional units of RNA genes are the 
mature noncoding transcripts and not the DNA sequences that encode them 
(Palazzo and Lee, 2015; Strachan and Read, 2018). 
There are at least three reasons why there is variation in the number of 
genes observed in the human genome: first reason, as mentioned above, 
stems from some difficulties in defining the genes because their classical view 
as discrete entities has been challenged by atypical examples (such as 
overlapping genes, genes-within-genes, 'conjoined genes'); second, genes can 
vary in number between haplotypes due to structural variation; and third, 
updates of the reference genome and new releases of patches may refine the 
number of detected genes (Table 1). 
About 75% of the genome seems to be transcribed at least in some cells 
or at specific time points during development (Djebali et al, 2012). 
Noncoding transcripts are abundant, with largely uncharacterized functions. 
Also, the traditional division of genes into protein-coding and RNA genes has 
been challenged. The average human protein-coding gene produces about six 
to seven transcripts, with some being noncoding transcripts that may have 
functional roles. The reverse is also true when genes originally classified as 
encoding lncRNAs have been found to contain short sequences that encode 
micropeptides (Li and Liu, 2019). These examples suggest a substantial 
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Families of genes emerged through duplication events that led to increases in 
the human genome's functional diversity. These events involved duplications 
of single genes (Conrad and Antonarakis, 2007) or of larger chromosomal 
regions (Bailey et al, 2002), in addition to the evolutionarily ancient whole-
genome duplication. 
Pseudogenes are copies of a functional gene that have acquired 
inactivating mutations and can no longer produce the gene product. They can 
arise by copying genomic DNA sequences, as in the case of nonprocessed 
pseudogenes. Another mechanism is retrotransposition, when a processed 
RNA transcript is reverse-transcribed and reintegrated into the genome, as in 
the case of processed pseudogenes (Zheng and Gerstein, 2007). Retrogenes 
are intronless genes that arose by retrotransposition, acquired the ability to 
be expressed in the new genomic context, and retained their function under 
selective pressure (Kaessmann et al, 2009). 
The ENCODE project began in 2003 as a pilot study to define all 
functional elements in the human genome. The functional elements include 
protein- and RNA-genes, as well as regulatory elements (promoters, 
enhancers, repressors/silencers, insulators) (Kellis et al, 2014). In general, 
functional elements are considered DNA stretches that encode a defined 
product or present a reproducible biochemical signature, such as 
transcription or a specific chromatin structure (ENCODE Project 
Consortium, 2011). The ENCODE reports showed initial evidence for 
~400,000 regions with features of enhancers and >70,000 promoter-like 
Table 1. Statistics of human genes. 
Data from NCBI, GRCh38.p12 (released in December 2017) at 
www.ncbi.nlm.nih.gov/genome/annotation_euk/Homo_sapiens/109/ 






Genes and pseudogenes 54,644 60,669 
Protein-coding genes 20,203 19,959 
mRNAs 113,620 84,068 





46,854 48,479 (lncRNAs) 






regions (ENCODE Project Consortium, 2012). Their finding that over 80% of 
the human genome is either transcribed or participates in an RNA or 
chromatin-associated event was broadly interpreted that the 'junk DNA' 
concept should be abandoned. This idea, however, met strong resistance 
from evolutionary geneticists (Germain et al, 2014; Palazzo and Gregory, 
2014). 
Over two-thirds of the human genome consists of repetitive sequences 
(de Koning et al, 2011). They encompass high copy number tandem repeats 
(satellite, minisatellite, and microsatellite DNA) and transposon repeats 
(DNA transposons and retrotransposons). 
Among tandem repeats, satellite DNA primarily associates with highly 
condensed, constitutive heterochromatin. Nevertheless, these sequences can 
be transcribed, as it is the case for DNA in telomere heterochromatin, with 
the resulting transcripts regulating different aspects of telomere biology 
[reviewed in (Biscotti et al, 2015)]. 
The majority of the human genome sequence originates from 
transposons, DNA elements that can move from one genomic location to 
another. The great majority of transposons in the human genome moved by a 
'copy-and-paste' mechanism (retrotransposons) and a minority by 'cut-and-
paste' (DNA transposons). Most human transposon sequences are now 
inactive, as they acquired inactivating mutations or lost functional elements 
[reviewed by (Goodier, 2016)], but sometimes they can cause human disease 
(Hancks and Kazazian, 2012). 
2.1.3. MITOCHONDRIAL DNA 
Human mtDNA is typically maternally inherited, with rare observed 
instances of biparental inheritance (Luo et al, 2018; McWilliams and 
Suomalainen, 2019; Schwartz and Vissing, 2002). In most cases, paternal 
mtDNA is degraded after fertilization by a poorly understood mechanism 
that in Caenorhabditis elegans involves endonuclease G, autophagy, and 
proteasome degradation pathways (Zhou et al, 2016). 
As already mentioned, mitochondria have a multicopy genome, but this 
does not necessarily imply that all mtDNA molecules are identical. Variation 
in the mtDNA sequence gives rise to heteroplasmy, a phenomenon where 
some of the mtDNA molecules in the cell vary in sequence from others 
(Figure 1). The sequence variation can be (nearly) neutral, or pathogenic. A 
high-level heteroplasmy of an mtDNA mutation is associated with disease. 
In the development of a female, the process of oocyte formation may lead 
to very different mtDNA heteroplasmy levels that can be transmitted to 
offsprings. Therefore, the fate of future offsprings is determined in the early 
life of a mother-to-be. The phenomenon has been termed 'mitochondrial 
bottleneck', a concept borrowed from population genetics because a small 
number of mitochondrial DNA molecules allows the drift of heteroplasmy in 
the oocytes. There is a debate on whether the bottleneck occurs in the early 
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or later stages of oocyte development. Although mtDNA has ~100 fold higher 
mutation rare than nDNA, evidence exists for mechanisms of purifying 
selection against the transmission of certain mtDNA mutations [reviewed by 




Figure 1. Mitochondrial DNA heteroplasmy. A high heteroplasmy 
level for a mutant mtDNA is associated with disease. 
 
MtDNA is gene-dense, without introns, encoding 13 proteins of the oxidative 
phosphorylation system (OXPHOS), as well as two rRNAs and 22 tRNAs that 
enable the translation of the 13 proteins on mitochondrial ribosomes. A small 
stretch of noncoding DNA forms a structure called displacement loop (D-
loop), which contains major regulatory elements for replication and 
transcription initiation (Falkenberg et al, 2007). Unlike the DNA in the 
nucleus, mtDNA does not associate with histones but is complexed with 
other proteins of the matrix to form nucleoids, connected to the inner 
mitochondrial membrane. Each nucleoid typically contains a single mtDNA 
molecule, protected and bent by a high amount of transcription factor A 
(TFAM) (Ngo et al, 2014). 
2.1.4. COMPLEX CONTROL OF GENOME EXPRESSION 
The 100 Mb genome of C. elegans, a 1 mm long nematode, consists of six 
chromosomal pairs but contains about the same number of protein-coding 
genes as the human genome (Hillier et al, 2005). Where does the difference 
in complexity come from? The answer may not be straightforward. However, 
the observation that humans have many more RNA genes (~17,800 in 
human versus ~1,300 in worm, www.wormbook.org), with roles in 
regulating gene expression, suggests that the differences may rely mostly on 
the complex control mechanisms of human genome expression. The control 
of gene expression happens at multiple levels: DNA accessibility, 
transcription, translation, mRNA turnover, mRNA or protein localization, 
and protein stability. 
The regulation of gene expression at the cellular level takes place 
continuously, both in short-term as response to external signals and in long-
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term as part of specific cellular and tissue identity. The transcriptome and 
proteome vary considerably in different cell types, and the mechanisms that 
govern the stable tissue-specific identity are epigenetic. Therefore, we can say 
that the characteristic form and behavior of different cell types result from 
different epigenetically determined readouts of the same genome (Strachan 
and Read, 2018). 
First, to transcribe a gene, the DNA must be accessible, not buried in 
densely packed chromatin (Sivakumar et al, 2019). As discussed before, 
chromatin conformation plays a crucial role in the regulation of gene 
expression. Chemical modifications of DNA and histones shape the local 
chromatin organization. Participants in this process are enzymes that 
methylate cytosines in DNA, enzymes that modify histones in nucleosomes, 
proteins that bind methylated DNA or modified histones, and ATP-driven 
chromatin remodeling complexes that can change the positions of 
nucleosomes (Flaus and Owen-Hughes, 2011). DNA methylation modifies the 
functional state of regulatory regions but preserves the Watson-Crick base 
pairing of methylated cytosine. DNA methylation represents the classical 
epigenetic mark. It is involved in many forms of stable epigenetic repression: 
imprinting, X-chromosome inactivation, silencing of repetitive DNA, and 
tissue-specific gene expression. In vertebrates, heritable methylation occurs 
only at CpG dinucleotides (Schübeler, 2015). 
Transcription of a gene requires the transcription initiation complex to 
be assembled on the promoter. DNA looping brings distant sites close to the 
promoter, influencing its activity. The promoter activity is affected by 
sequence-specific DNA-binding proteins that bind either directly to the 
promoter or at more distant places, such as enhancers and repressors 
(Venkatesh and Workman, 2015). Co-activators and co-repressors do not 
bind DNA but are recruited by protein-protein interactions (Schoenfelder 
and Fraser, 2019). 
Protein translation is another control level for gene expression. This 
control often depends on miRNAs that bind to sequences in the 3' 
untranslated region of mRNAs (Bartel, 2009). Moreover, translation has a 
complex regulation at the level of ribosome-mRNA interaction, with specific 
factors promoting the preferential translation of mRNA subsets. A few 
examples include regulation of cap-dependant (Richter and Sonenberg, 
2005) and cap-independent translation (Walters and Thompson, 2016), or 
the synthesis of selenoproteins (Kossinova et al, 2013). 
Mitochondria have specific ribosomes, which translate the 13 OXPHOS 
subunits encoded by mtDNA. However, >99% of the proteins residing inside 
mitochondria are specified by nuclear genes and translated on cytoplasmic 
ribosomes. They are imported into mitochondria through transmembrane 
translocase complexes (TIM-TOM), often co-translationally. This process 
also applies to the remaining 79 nuclear-encoded OXPHOS components. 
Further, different proteases, chaperones, and assembly factors assist in 
forming the inner membrane complexes from the dual origin subunits 
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(Pearce et al, 2017) (Figure 2). Mitochondrial and cytosolic translation seem 
to be dynamically regulated for the synthesis of OXPHOS components. 
Studies in yeast have shown that cytosolic translation controls mitochondrial 




Figure 2. Coordination of cytoplasmic and mitochondrial 
translation in the synthesis of OXPHOS components. 
 
Besides the epigenetic mechanisms involved in cell identity and tissue-
specific regulation, two other significant examples of epigenetic processes are 
X-inactivation and imprinting. In female cells, a randomly-selected X 
chromosome is inactivated at the blastocyst stage of embryogenesis (Deng et 
al, 2014). All daughter cells will inactivate the same X as the mother cell. This 
process depends on Xist lncRNA, expressed only from the inactive X, 
physically coating it, and repressing gene expression (Chang and Brown, 
2010; Moindrot and Brockdorff, 2016). About 15% of X-linked genes escape 
inactivation, at least in some tissues and in some individuals. There are two 
pseudoautosomal regions that escape inactivation, but in general, X 
inactivation is patchy (Carrel and Willard, 2005). Epigenetic marks are 
usually erased at meiosis, but various instances exist when they are 
transmitted from parent to offspring. Such an example is imprinting, 
whereby alleles at a locus carry marks of their parental origin, which 
ultimately specify their expression. This effect has been described for a few 
dozen human genes (Soellner et al, 2017). Apart from these well-
characterized imprinted genes, other effects of transgenerational epigenetic 
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memory seem to exist, but their conceptual framework is poorly defined 
(Miska and Ferguson-Smith, 2016). 
2.2. VARIATION OF THE HUMAN GENOME IN HEALTH 
AND DISEASE 
2.2.1. DEFINITION AND TYPES OF VARIANTS 
The DNA sequence of the genome determines, together with environmental 
factors, the characteristics of each individual. Sequence variation underlies 
traits, such as height and eye color, but also disorders. 
The genetic variation encompasses all the permanent changes in the 
DNA sequence of the genome. Therefore, variants are any differences 
between newly generated genetic data and the reference genome. Variants 
range from single nucleotide changes to gains and losses of whole 
chromosomes, with the following main types [reviewed by (Lappalainen et al, 
2019)]: 
Single-nucleotide variants (SNVs) are changes of one DNA base to 
another, estimated to be around 3-4 million per genome. Multi-nucleotide 
variants (MNVs) are clusters of two or more nearby variants, with functional 
consequences that may differ from individual ones when they reside within 
the same codon (Wang et al, 2020). 
Small insertions and deletions (indels) are gains or losses of genetic 
material <50bp, estimated at 0.4-0.5 million in a typical genome. SNVs and 
indels represent the vast majority of variation in the human population. 
While most of this variation has no or little functional impact, some can 
cause severe disorders. 
Structural variation (SV) is a larger scale type of variation, quite diverse, 
defined by ≥50 bp in size. It includes copy-number variants (CNVs), 
rearrangements, and mobile element insertions. SVs are fewer in number in 
an average genome comparing with SNVs and indels, accounting for 
approximately 0.2% of total variants. Typically they have a larger functional 
impact owing to their size (Sudmant et al, 2015). SVs can disrupt genes and 
alter gene dosage, rearrange regulatory elements and genomic context. 
Identifying different SV classes may require distinct technological and 
algorithmic approaches (Audano et al, 2019). 
Tandem repeat variation comprises three classes: (1) short tandem 
repeats (STRs or microsatellites, which have the repeat unit of 1-6 bp), (2) 
variable number tandem repeats (VNTRs or minisatellites, with 7-49 bp 
repeat unit), (3) centromeric and heterochromatin repeats (satellite DNA, 
with various size repeat unit). Tandem repeats are the most challenging 
forms of variation to detect with current sequencing technologies. 
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2.2.2. CAUSES OF GENETIC VARIATION 
Genetic variants result from DNA changes that have not been corrected by 
the cellular repair systems (Shendure and Akey, 2015). No cellular process 
(e.g., DNA repair system) or enzyme (e.g., DNA polymerase) can function 
with 100% efficiency (Barnes and Lindahl, 2004). As a consequence, it is 
thought that endogenous factors determine the majority of genetic variants. 
Occasionally, external mutagens cause DNA changes. Such mutagens are 
radiation and chemicals in our environment. The molecular sources of DNA 
changes are errors in chromosome segregation and recombination, DNA 
replication and repair, and chemical damage to DNA. 
In early development, chromosome segregation errors can give rise to 
embryos with an altered number of DNA molecules (such as Down 
syndrome). In somatic cells, the altered chromosome number is a feature of 
many cancers. CNVs are typically caused by mispaired recombination during 
meiosis or recombination-like mechanisms in somatic cells (Conrad et al, 
2010). CNV formation also has a complex and poorly understood connection 
with early/late replication timing of the DNA (Chen et al, 2014). SNVs, 
MNVs, and indels typically arise during DNA replication (random 
polymerase errors and polymerase slippage at tandem repeats) or as a 
consequence of chemical damage to DNA (strand breakage, base deletion, 
base modification, and cross-linking). 
There are two categories of molecular pathways dedicated to DNA repair 
[reviewed by (Chatterjee and Walker, 2017)]: 1) pathways that repair single-
stranded damage and 2) the repair of double-stranded damage. Failures in 
these processes lead to permanent sequence alterations. The alterations are 
transmitted to all daughter cells when they occur in dividing somatic cells or 
to offspring if they occur in germline cells. 
However, variants do not exist evenly across the genome. There are so-
called 'mutation hotspots'. For example, CpG deamination causes more C to 
T transitions than other dinucleotide pairs. Repeat junctions are another 
example of sites prone to variation due to polymerase slippage during 
replication. Moreover, DNA regions with late replication timing associate 
with higher SNPs in the population, higher newly formed point mutations, 
and CNVs [reviewed by (Chen et al, 2014)]. The estimated rate of germline 
SNVs is 1.2x10-8 per base per generation, about 63 new mutations per 
person, but in CpG sites, the rate is 1.12x10-7 (Kong et al, 2012). Germline 
MNV rate is estimated to be only 1–3% of the SNV rate (Wang et al, 2020). 
Moreover, germline mutations are mostly of paternal origin, and they 
increase in number with paternal age, although a maternal age effect was also 






2.2.3. THE SPECTRUM OF GENETIC VARIATION AND POPULATION 
HISTORY 
Human population history, with ancient bottlenecks and recent expansion, is 
reflected in variant allele frequencies. A criterion to classify the variants is 
the minor allele frequency (MAF). Based on MAF, the variants are: common 
(>5%), low-frequency (1-5%), rare (<1%), and ultra-rare (<0.01%) 
(Lappalainen et al, 2019). If we look at the individual level, most variants are 
common because they arose early in human history and are now present in 
all major ancestry groups. However, at the population level, most variants 
are ultra-rare, resulting from recent generations of population growth, with 
50-100 new mutations occurring in each individual (Ralph and Coop, 2013). 
Allele frequency reflects both allele's age and the selective forces acting on it. 
A low allele frequency may indicate a recent variant in population or a 
deleterious variant that is inefficiently passed on to new generations, or both. 
In the light of purifying selection, we can understand that most deleterious 
variants are rare because they affect reproductive fitness. For this reason, a 
small allele frequency is the primary variant prioritization criterion in severe 
Mendelian disorders with strong effects on reproductive fitness. Presently, 
the most accurate allele frequency estimates come from the databases 
gnomAD (https://gnomad.broadinstitute.org/) and SISu for the Finnish 
population (http://www.sisuproject.fi/). However, these databases do not 
contain structural and repetitive variants, and larger indels are also limited. 
Isolated populations resulting from recent bottlenecks typically display a 
lower level of rare neutral variation and an enrichment in functional and 
even deleterious variants. Some of these variants can be present at relatively 
high frequencies, a consequence of increased drift and reduced selective 
pressure. Finland is an example of such an isolated population with multiple 
historical bottlenecks (Chheda et al, 2017). The population bottlenecks 
appeared when small groups of settlers inhabited remote, isolated areas, with 
the resulting populations further subjected to famine periods. The dual 
theory of Finland’s inhabitation postulates an early migration wave into 
Finland from the east ~4,000 years ago involving eastern Uralic speakers, 
followed by a later migration ~2,000 years ago from the south, involving 
Indo-European speakers (Peltonen et al, 1999). Additional significant 
migratory movements were within Finland in the 16th century in the eastern 
and northern parts (Norio, 2003a). 
These historical events caused the enrichment of some disease-causing 
variants and others' losses, a phenomenon known as the founder effect. The 
concept of 'Finnish disease heritage' was introduced in 1973 (Norio et al, 
1973) and describes presently 36 monogenic diseases more frequent in 
Finland than in any other population (Norio, 2003b). It is a consequence of 
how founder effects and genetic isolation have shaped the Finns' gene pool. 
Most Finnish heritage diseases have an autosomal recessive mode of 
inheritance, while two are autosomal dominant, and two X-linked. The 
genetic causes for 35 of these diseases have been characterized, with the 
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particularity that one founder mutation accounts for 70-100% of disease 
alleles (http://www.findis.org/index.php). 
2.2.4. GENETIC VARIATION IN HUMAN DISEASE 
Each human genome contains ~4 million SNVs and indels (Pelak et al, 2010), 
of which ~25,000 occur in protein-coding regions. Already about five 
decades ago, it was postulated that the vast majority of genetic variation is 
neutral (Kimura, 1968) or nearly neutral (Ohta, 1973) and does not have a 
dramatic evolutionary effect. Supporting this view, data from genome 
sequencing projects have shown that the human genome can tolerate a large 
degree of variation without any apparent pathogenic effect. For example, a 
typical human genome contains ~100 rare loss-of-function variants, which 
are predicted to disrupt the gene function, with ~20 genes being completely 
inactivated (MacArthur et al, 2012). 
However, not all of the genetic variation is neutral or without phenotypic 
effect. Some variants increase susceptibility to certain disorders or even 
directly cause them. Moreover, genetic variants can also be advantageous and 
positively selected during evolution (Hurst, 2009). Developmental genes 
typically tolerate little variation in the amino acid sequence, whereas 
nonessential genes can sometimes be completely knocked out without 
phenotypic effect (Sulem et al, 2015). Given that proteins represent essential 
functional elements of the cell, it is no surprise that much of the deleterious 
variation eliminated by negative selection resides within the exome. Along 
this line, the 1000 Genomes Project showed that exons have 50% less genetic 
diversity compared to introns (The 1000 Genomes Project Consortium, 
2010). However, awareness has been raised on the importance of noncoding 
variation for human disease. For example, many variants that predispose to 
multifactorial diseases are located in regulatory regions that affect gene 
expression levels. Noncoding variation can also have a dramatic effect on 
gene function, for example, by disrupting splicing. 
Genetic variants can be classified based on their consequence on the gene 
product (Strachan and Read, 2018). Loss-of-function variants result in 
abolished function. A decreased function characterizes hypomorphic 
variants. Dominant-negative variants can disrupt the function of the wild-
type allele. Gain-of-function variants cause an enhanced or altered function, 
for example, a kinase that is always in an active conformation. 
Another classification of variants specifies their effect on the protein 
sequence. Silent or synonymous variants do not change the amino acid 
sequence, whereas missense variants cause a substitution of an amino acid 
residue to another. Typical loss-of-function DNA changes include splice site 
(disrupt splicing), nonsense (premature stop codon), and frameshift indel 
(disrupt reading frame) variants. However, these types of variants do not 
always cause loss of function. For example, when a nonsense or frameshift 
variant occurs at the end of the gene's coding sequence, and to a smaller 
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extent for those at the very beginning (MacArthur et al, 2012). On the other 
hand, noncoding, missense, and synonymous variants can have complete 
loss-of-function consequences. An example constitutes recently-described 
variants in UTR regions (Whiffin et al, 2020) that prevent the ribosome from 
correctly translating the mRNA. Some additional examples are missense 
changes that disrupt catalytically active residues or induce protein instability, 
along with synonymous and deep intronic variants that disrupt splicing. 
2.3. GENETICS OF RARE DISORDERS AND NEXT-
GENERATION SEQUENCING 
2.3.1. DEFINITION AND GENETIC ARCHITECTURE OF RARE 
DISORDERS 
Rare disorders are defined as life-threatening or chronically debilitating 
disorders with a prevalence of less than 1:2,000 in the population and are 
mostly genetic in origin. Around 7,000 rare disorders have been reported, 
with new syndromes continuously being described. With ~350 million people 
suffering from rare disorders worldwide, among which 50-75% being 
children, they are common overall (Claussnitzer et al, 2020). Rare disorders 
are not only severe and chronic but also often difficult to diagnose and 
without adequate treatment. Understanding their genetic etiology is pivotal 
for choosing the best available treatment, as well as for promoting research 
towards the development of improved, targeted treatments. 
The heritability of rare genetic diseases typically follows the simple rules 
of inheritance proposed by Gregor Mendel in the 19th century; therefore, 
they are also called Mendelian. This type of inheritance is a consequence of 
genetic defects that are fully penetrant and affect a single gene. For this 
reason, they are also considered monogenic (Strachan and Read, 2018). An 
autosomal recessive disease develops if deleterious variants affect both 
copies of the gene. X-linked recessive disorders affect primarily males when 
their unique copy of the X chromosome carries the defect. Females can be 
mildly and variably affected, depending on their X chromosome inactivation. 
Loss-of-function or hypomorphic variants typically underlie recessive 
diseases. A dominant disease is caused by heterozygous variation that can be 
gain-of-function, loss-of-function (haploinsufficient diseases), or dominant-
negative. 
De novo variants are new sequence changes that occur either in parental 
germline cells (sometimes mosaic in a parent) or at some point after 
conception. They contribute to human diseases and, when they affect the 
individual's reproductive fitness, are not transmitted to the next generations 
(Veltman and Brunner, 2012). At healthy population level, this severe 
variation does not exist. 
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Somatic mutations are not inherited; they affect a subset of cells in the 
body and are de novo genetic variants that occur after conception in any cell 
type except germ cells. Although they have been studied broadly in cancer, 
their role in rare and common disorders has also been increasingly 
recognized (Li and Williams, 2013). 
Discovering the disease-causing variants in rare disorders is very 
important for adequate treatment of patients, for assessing disease 
prognosis, and for genetic counseling of the family. A genetic diagnosis can 
also reduce the number of tests, medical appointments, and the emotional 
burden associated with the illness. Moreover, there is a scientific purpose 
beyond patient care, as the association of a phenotype to a gene typically 
brings knowledge on the gene function and related cellular pathways. 
2.3.2. TRADITIONAL AND MODERN GENETIC APPROACHES IN RARE 
DISORDERS 
Five years ago, the estimated discovery of causative genes in all known 
Mendelian disorders was 50% (Chong et al, 2015). Consequently, there are 
still many novel disease genes to uncover, with the additional consideration 
that many new disorders are still uncharacterized (Bamshad et al, 2019). 
This view agrees with the ExAC findings, where over 3,000 genes are nearly 
depleted of protein-truncating variants, 72% of them without any present 
disease association (Lek et al, 2016). 
Compared to multifactorial, complex conditions, Mendelian disorders' 
simpler genetic architecture positioned them on the front line of gene 
discovery for a long time. Disease gene mapping (localization of disease 
genes using proxies) started in the 1980s, marked by mapping of 
Huntington's disease gene to chromosome 4 (Gusella et al, 1983). During the 
next two decades, gene discovery studies employed mainly genome-wide 
linkage analysis, using polymorphic genetic markers that segregate together 
with the disease locus in large pedigrees. This method was able to identify the 
chromosomal region of a disease gene, sometimes further combined with 
positional cloning to isolate and characterize the gene. Other successfully 
employed methods were karyotyping and homozygosity mapping (Strachan 
and Read, 2018). These methods allowed the identification of numerous 
disease loci, but the genetic findings were limited to large family pedigrees or 
diseases with a particular clinical presentation. 
Moreover, disease gene mapping in isolated populations, such as Finland 
and Iceland, was incredibly successful because of reduced genetic 
heterogeneity originating from population bottlenecks in the early phases of 
population history (Nelis et al, 2009). Traditional methods were 
underpowered to detect genetic components of complex diseases because the 
effect sizes of the underlying variants are small compared to Mendelian 
disorders. The traditional methods also do not tolerate high genetic or 
phenotypic heterogeneity (Strachan and Read, 2018). 
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The 'first-generation' DNA sequencing method was the dideoxy chain-
termination developed by Frederick Sanger in the 1970s, the reason for 
which it is also called 'Sanger sequencing' (Sanger and Coulson, 1975; Sanger 
et al, 1977). The initial gel-based method was subsequently multiplexed and 
automatized for the detection of products through capillary electrophoresis. 
Sanger sequencing played a crucial role in the Human Genome Project, but 
today applies to small-scale applications such as confirmation of variants or 
rarely to a candidate gene screening (Shendure et al, 2017). 
The 'Next-Generation Sequencing' (NGS) era started in 2005 by 
introducing the first commercial sequencing machine, generating low-cost, 
high-throughput sequence data. A few chemistries are underlying different 
NGS technologies. One of the most widely used is sequencing-by-synthesis, 
initially developed at Solexa and later acquired by Illumina. This method 
produces short sequence reads, 50-300 bp in length, making their alignment 
to the reference genome more challenging and limiting the method's capacity 
to detect repeat variation and complex genomic rearrangements (DePristo et 
al, 2011). 
The 'third-generation sequencing' started with introducing single-
molecule technologies (Pacific Biosciences and Oxford Nanopore 
Technologies), capable of producing long-read data. However, they are not 
yet widely used because of high error rates, high costs, and fewer 
bioinformatic tools developed (Heather and Chain, 2016) 
The automation and standardization of short-read NGS technologies 
determined to be widely adopted and promoted a shift in costs and 
challenges from the sequencing process itself on the storage capacity, 
bioinformatic analysis, and interpretation of the data. 
2.3.3. NEXT-GENERATION SEQUENCING IN GENE DISCOVERY AND 
DIAGNOSIS OF RARE DISORDERS 
NGS technologies have revolutionized gene discovery in human diseases and 
made it possible to decipher the genetic basis of phenotypically and 
genetically heterogeneous disorders, a challenge for traditional methods 
(Wright et al, 2018). 
Figure 3 summarizes the gene discovery pace in rare disorders, marking 
the advancements in research resources and key scientific findings by NGS, 
with focus on cadiomyopathy. 
The collection of large cohorts of patients often comes with the cost of a 
shallow phenotypic description. NGS-based methods enable using the 
'genotype-first' or 'reverse phenotyping' approach, when the precise 
diagnosis is established primarily on the genetic data. NGS technologies 
allow the evaluation of all annotated variants in a hypothesis-free manner, 
important especially in phenotypically heterogeneous diseases (Bacchelli and 
Williams, 2016). 




Figure 3. Gene discovery in rare disorders. Significant resources and 
key findings by NGS in cardiomyopathies. Adapted after Claussnitzer et al, 
2019. The publication of the human genome draft in 2001 was a significant 
milestone for biology and medicine. The human genome, together with the 
introduction of the first commercially available NGS machines in 2005, 
sparkled the field of human genetics. The first disease gene uncovered by 
NGS was MYH3 in distal arthrogryposis type 2A (Ng et al, 2009). Among the 
first disease genes that cause a mitochondrial disorder uncovered by NGS 
were ACAD9 (Haack et al, 2010) and AARS2 (Götz et al, 2011), both 
presenting with hypertrophic cardiomyopathy. 
 
Classical genetic methods relied on delimitating subgroups of patients with a 
specific and consistent clinical presentation, as well as on large family 
pedigrees to assert the shared genetic background. The variability of 
 
30 
symptoms in many disorders was limiting for clinical recognition of 
etiological subgroups. 
Moreover, the hypothesis-free approaches allow expansion of the 
phenotypic spectrum of already known disease genes to completely different 
disorders without shared symptoms. For example, AARS2 is a nuclear gene 
that encodes a mitochondrial protein and was initially described in neonatal 
fatal hypertrophic cardiomyopathy (Götz et al, 2011). However, it has also 
been later reported in leukodystrophy with ovarian failure (Dallabona et al, 
2014). 
There are three main NGS-based applications in human genetics: gene 
panels, whole-exome sequencing (WES), and whole-genome sequencing 
(WGS) [reviewed in (Fernandez-Marmiesse et al, 2018; Maroilley and 
Tarailo-Graovac, 2019)]. 
Gene panel sequencing typically targets known disease genes, most often 
only the coding parts and intron-exon boundaries. Panels can range from one 
to thousands of genes. The most comprehensive panel targets all exons of 
known Mendelian genes (e.g., TruSight One Expanded Sequencing Panel 
from Illumina, covering ~6700 genes). By focused analysis, gene panels are 
timesaving, cost-effective, and preferred when the clinical phenotype is 
suggestive for a specific disorder with well-characterized genetic background. 
They are also useful to screen a replication cohort for candidate genes 
identified in a discovery cohort or when high coverage is essential, for 
example, to uncover somatic mutations. Another benefit of panels is that they 
can reliably exclude known disease genes due to adequate coverage and 
depth (Rehm, 2013). Their limitations include missing the genetic diagnosis 
as a consequence of the phenotypic and genetic heterogeneity of the disease, 
multiple overlapping diagnoses not all represented in the panel, novel 
disease genes, as well as types of genetic variation not detected by panels 
(such as noncoding variants and SVs). 
Whole-exome sequencing (WES) enables a more comprehensive 
molecular diagnostic approach, targeting virtually all protein-coding genes in 
the genome. Given that the exome constitutes only ~1.1% of the genome and 
contains a large proportion of the variation involved in monogenic disorders, 
WES is a cost-effective method (<500€/sample) that facilitated 
unprecedented discoveries in the last decade. WES typically has been the 
next step when gene panel testing was negative. Further, it is preferred when 
the phenotype is unspecific for a panel or in disorders with high genetic 
heterogeneity, with hundreds of disease genes. 
The first gene discovered by WES was published in 2009 (Ng et al, 
2009). Since then, many genetic discoveries have involved novel disease 
genes, novel genotype-phenotype correlations, somatic mosaicism, or novel 
causes of phenotypic variability (double mutations, genetic modifiers, 
multiple diagnoses). WES' success rate varies widely with disease type, 
patient selection criteria, and type of test applied (singleton versus trio-WES, 
the latter including the patient and two unaffected family members, most 
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often parents). The overall diagnosis rate of trio-WES in rare disorders 
ranges between 30 and 50% (Chung et al, 2020; Fitzgerald et al, 2015; 
Sawyer et al, 2016), a significant improvement comparing to 10% diagnosis 
with traditional methods (Wright et al, 2018). Many of these patients, 
however, undergo different types of genetic investigations beforehand. When 
WES was used as a first-line genetic test in infants with a suspected 
monogenic disorder, the diagnosis yield amounted to 58%. In contrast, the 
standard care approach, which included panel sequencing when clinically 
indicated, led to a 14% diagnosis in the same individuals (Stark et al, 2016). 
Nevertheless, there are still many limitations to the method, including an 
unequal coverage depth between different genomic regions, with GC-rich 
areas particularly challenging to cover. An additional limitation is the 
inability of WES to detect all genomic variation like functional noncoding 
variants (deep intronic variants affecting splicing, regulatory elements, 
functional noncoding RNAs), SVs, and repeats. Recent capture kits enable 
better target coverage and also capture some functional RNA genes. For 
example, the capture kits from different companies can isolate 40-60 Mb of 
DNA, representing 1.5-2% of the genome. These DNA regions consist of 
~180,000 protein-coding exons plus a variable amount of intronic and 
regulatory sequences, as well as different RNA genes. WES has lower 
sensitivity and resolution to detect CNVs than other approaches, with only a 
minority of CNVs being identifiable from short read depth analysis. 
Whole-genome sequencing (WGS) is the most comprehensive approach, 
with the potential to identify every genetic variation that plays a role in 
human biology. Over the next few years, once prices come down sufficiently, 
WGS will become the predominant technology for genetic analysis. The main 
advantage of WGS is the avoidance of exon capture because this process 
often leads to uncovered coding sequences in WES (Lelieveld et al, 2015). 
There are examples when WGS found pathogenic coding variants after a 
negative WES analysis on the same samples (Alfares et al, 2018). Most 
variants in noncoding sequences are uninterpretable in the present state of 
knowledge and are often not expected to be high-penetrance causes of 
disease. An additional benefit of WGS is the ability to detect and characterize 
SVs, which are relatively rare causes of Mendelian conditions but are crucial 
for tumor analysis. 
Currently, there are three general WGS strategies (Lappalainen et al, 
2019): (1) short-read WGS (Illumina mainly) with paired-end reads of ~150 
bp and low error rates in the range of 0.1-0.5%; (2) long-read WGS using 
single-molecule technologies (Pacific Biosciences and Oxford Nanopore 
Technologies) with 10-100 kb reads and high error rates in the range of 10-
15%; (3) linked-read WGS (10xGenomics) using Illumina bar-coded short-
reads derived from a single long molecule (of ~50kb) and assembled in silico. 
Given the accuracy, ease of use, and costs, most studies employ Illumina 
short-read technology. However, the short reads are challenging for accurate 
mapping of pseudogenes and tandem repeats, as well as for repeat expansion 
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and SV detection. All these types of variants are better detected by long-read 
sequencing, which has its own limitations related to high cost per sample, 
high error rates, lower throughput, and less bioinformatic tools developed. 
Holistic approaches may integrate short and long-read technologies, 
together with multiple bioinformatic approaches to detect variants and 
predict their functionality. Although the integration of data sources and tools 
is superior, its use is limited currently by time, costs, and expertise. 
The higher costs (~double WES), additional computational burden, less 
bioinformatic tools, and limited functional interpretation of noncoding 
variants have restricted the use of WGS.  
As laboratories transition from gene panels to WES and WGS, genetic 
information on additional disease susceptibility loci can be detected in the 
patient data. Ethical considerations have been raised related to their 
disclosure (Christenhusz et al, 2013). These are incidental and secondary 
findings, defined as genetic test results that provide information about 
known or expected pathogenic variants in a gene unrelated to the test's 
primary purpose. The second condition might not be manifesting yet (Roche 
and Berg, 2015). 
The American College of Medical Genetics and Genomics (ACMG) 
developed a set of recommendations on reporting the incidental and 
secondary findings, first in 2013 (Green et al, 2013), with an update in 2017 
(Kalia et al, 2017). They defined secondary findings as those in genes 
intentionally analyzed from a defined list, while incidental findings are 
discovered non-intentionally. The aim is to identify and manage the risk for 
highly penetrant genetic disorders with established interventions that 
prevent or significantly reduce morbidity and mortality (Saelaert et al, 2018). 
The updated list includes 59 medically actionable genes associated with 
cancers, cardiomyopathies, arrhythmogenic disorders, and other life-
threatening conditions (Kalia et al, 2017). The recommendation is to report 
only pathogenic or likely pathogenic variants in these genes (class 5 and 4 on 
ACMG criteria of variant pathogenicity), but not variants of unknown 
significance (VUS), whose involvement in disease at the time of analysis is 
unclear. 
The secondary findings may help prevent diseases or guide their 
management, but they can also cause anxiety for individuals and families. 
For this reason, the patient or family can choose to 'opt-out' the analysis of 
the secondary findings (Saelaert et al, 2019). Soon, it is expected the 
incorporation of selected pharmacogenomics variants to the minimum 
secondary finding screening list because of known variants and haplotypes 
that dramatically modify the metabolism of specific drugs, with potentially 
severe side effects (Caudle et al, 2014; Hicks et al, 2018). 
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2.4. LEUKOENCEPHALOPATHIES 
2.4.1. MYELIN IN THE CNS 
The central nervous system (CNS) broadly consists of gray matter structures, 
defined by the densely packed cell bodies, dendrites, and synapses, 
connected by extensive white matter tracts, which are defined by the heavily 
myelinated axons. Besides the myelinated axons, the white matter contains 
numerous glial cells (oligodendrocytes, astrocytes, microglia) and nourishing 
blood vessels. On a dry weight basis, 40-50% of white matter is myelin. 
Comparing with other plasma membranes, myelin presents a unique 
composition with low water content (40%) and very high lipid content. Dry 
myelin is 70% lipids and 30% proteins, in contrast to most biological 
membranes with a higher ratio of proteins to lipids (Morell and Quarles, 
1999a). 
In the CNS, the myelin sheath is a modified oligodendrocyte plasma 
membrane that extends and surrounds in a spiral a segment of an axon 
(Stassart et al, 2018). One oligodendrocyte may form myelin segments on up 
to 40 axons. However, on the same axon, adjacent myelin segments belong to 
different oligodendrocytes. The nodes of Ranvier are small unmyelinated 
axonal regions between two segments of myelin and contain clusters of 
voltage-gated sodium channels that allow membrane depolarization (Salzer, 
1997). The high resistance and low capacitance of myelin determine the 
electrical impulse to jump from node to node, which represents the basis of 
saltatory, fast nerve conduction, crucial for functional integration of the CNS 
(Cohen et al, 2020). 
Myelination starts during the fifth month of fetal life in the spinal cord. It 
peaks during the first year of life and progresses slowly until around 20 years 
of age in some cortical fibers, especially in associative areas (Morell and 
Quarles, 1999b). Active myelination is a tightly regulated cellular and 
molecular process, but also more vulnerable to insults. In contrast, mature 
myelin is relatively stable and resistant to alterations (Williamson and Lyons, 
2018). 
2.4.2. CLINICAL ASPECTS OF LEUKOENCEPHALOPATHIES 
Failure of white matter formation or maintenance in the CNS appears in 
heritable conditions termed leukoencephalopathies and leukodystrophies, 
which may or may not present peripheral nervous system involvement. 
The incidence of pediatric heritable leukoencephalopathies and 
leukodystrophies is not clearly established due to diagnosis challenges. Their 
estimated combined incidence ranges from 1:50,000 (Heim et al, 1997) to 
1:8,000 (Bonkowsky et al, 2010). 
Most leukoencephalopathies and leukodystrophies present with motor 
symptoms. In an infant or young child, the manifestation can be delayed 
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acquisition or regression of motor skills. In older children, the first signs can 
be frequent falls or a clumsy gate, and in adolescents, deterioration of sports 
activities. In addition to neurological symptoms, several other red flags are 
suggestive of a white matter disorder: endocrine disturbances, dysmorphic 
facial features, ophthalmologic abnormalities, cortical visual impairment, 
hearing impairment, dental, skin, tendinous, or skeletal abnormalities, 
hepatosplenomegaly, ovarian dysgenesis, and gastrointestinal symptoms 
(Parikh et al, 2015). 
Genetic leukoencephalopathies and leukodystrophies often have a 
pediatric onset and are caused by defects in any of the white matter 
structural components, including oligodendrocytes, astrocytes, microglia, 
axons, and blood vessels (van der Knaap and Bugiani, 2017). 
Leukodystrophies refer to those disorders in which glial cells are primarily 
affected. By definition, the pathology in leukoencephalopathies is primarily 
neuronal, vascular, or systemic, and the white matter changes occur 
secondarily or are not the predominant clinical picture (Vanderver et al, 
2015). 
White matter disorders may present different types of underlying 
pathology, most often in combination, and can be determined by both genetic 
and acquired factors (Stadelmann et al, 2019). Examples of encountered 
pathologies are: hypomyelination, when the myelin never reaches the normal 
developmental levels; dysmyelination, a disturbance that leads to irregular, 
patchy myelin; axonal degeneration is another pathology accompanied by 
myelin disturbance as a consequence of the interdependence between the 
axon and the myelin sheath; demyelination of previously normal myelin 
sheath; intramyelin vacuole formation, which may result in myelin splitting, 
with or without demyelination; and oligodendrocyte death, which affects 
both the formation and maintenance of myelin. 
Brain magnetic resonance imaging (MRI) is the most important clinical 
investigation in patients suspected of leukoencephalopathy or 
leukodystrophy. There are several types of MRI techniques, but fundamental 
to diagnosis are T1-weighted and T2- weighted images (Parikh et al, 2015). 
T1-weighted images are useful for revealing the anatomic structures in 
detail and assessing myelination in infants until 9-10 months old because 
small amounts of myelin are better visualized on these types of images. On 
T1-weighted images, normal white matter appears bright and cerebrospinal 
fluid (CSF) black. Pathological white matter gives a decreased signal and 
appears dark. 
T2-weighted images are superior in evaluating the pathological changes 
of white matter and the stage of myelination in subjects older than 9-10 
months. On T2-weighted images, normal white matter appears dark and CSF 
bright. Pathological white matter leads to abnormally high signal and 
appears bright. 
Other MRI investigations may be employed during diagnostic workup 
(such as FLAIR and diffusion-weighting imaging). Magnetic resonance 
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spectroscopy, which reveals biochemical changes in the brain, is useful in 
mitochondrial disorders and Canavan disease to assess lactate and N-acetyl 
aspartate, respectively. 
Following the MRI pattern analysis, the diagnostic approach aims to 
resolve the etiology as quickly as possible because some white matter 
disorders present established therapeutic interventions. For example, 
acquired white matter abnormalities that result from B12 (cobalamin) 
deficiency are reversible with vitamin supplementation. Some of the genetic 
leukoencephalopathies that present an established intervention include the 
amino acidemias (e.g., phenylketonuria), Wilson disease, and others. 
Biochemical testing is essential for a reliable diagnostic. A minimum set of 
tests includes plasma very-long-chain fatty acids, leukocyte lysosomal 
enzymes, blood lactate, pyruvate, and amino acids, urine sulfatides, and 
organic acids (Parikh et al, 2015). In parallel to biochemical tests, the 
diagnostic approach continues with genetic testing. 
2.4.3. GENETICS OF LEUKOENCEPHALOPATHIES 
The genetic defects leading to myelin disorders are heterogeneous (Parikh et 
al, 2015), with novel disease genes continuously being identified. Here we 
highlight several pathways commonly recognized in myelin disorders: a) 
maintenance of a balanced myelin lipid and protein composition b) synthesis 
and degradation of lipids c) secretory pathway and endoplasmic reticulum 
(ER) stress d) adherence of myelin sheath to axolemma and of multilamellar 
myelin membranes to each other e) axonal integrity and axon-myelin 
communication f) immunity activation g) astrocyte function and astrocyte-
oligodendrocyte communication h) cytoplasmic and mitochondrial 
translation i) amino acid metabolism j) mitochondrial metabolism. Table 2 
contains most of the genes described so far to cause white matter disorders. 
The genetic heterogeneity in white matter disorders is best addressed in 
genetic testing by NGS technology. Gene panel approaches, encompassing a 
minimum set of genes defining both disease groups, can be used but often 
are not sufficient. The number of novel genes is continuously increasing, and 
the phenotypic spectrum of disorders with secondary white matter 
involvement continues to broaden. A study suggested that detailed MRI 
pattern analysis coupled with NGS, may lead to a higher molecular diagnosis 
rate (Vanderver et al, 2016). A recent randomized trial of immediate WGS in 
pediatric white matter disorders showed quicker and greater diagnosis 







Table 2. Genetics of leukodystrophies and leukoencephalopathies. 
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OXPHOS – Oxidative phosphorylation 
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2.5. CARDIOMYOPATHIES 
2.5.1. DEFINITION AND TYPES OF CARDIOMYOPATHIES 
Childhood cardiomyopathies (CMPs) are rare but severe heart muscle 
disorders characterized by pathological changes of the myocardium, 
unexplained by abnormal loading conditions, or congenital heart disease 
(Lee Teresa M. et al, 2017). They present an annual incidence of about 
1:100,000 children worldwide, with the highest in infants under one year of 
age (Lipshultz et al, 2013). An epidemiology study from Finland estimated an 
annual incidence of 0.65:100,000 individuals up to 20 years of age, but this 
study included only idiopathic CMPs (Arola et al, 1997). The highest 
incidence emerged in an Australian study, with 1.24:100,000 children 
younger than ten years of age, a period when CMP is most typically 
diagnosed (Nugent et al, 2003). In a study from the United States, the annual 
incidence was 1.1:100,000 children younger than 18 years (Lipshultz et al, 
2003). 
CMPs present some of the least favorable prognoses in pediatric 
cardiology. In children, CMPs are more severe comparing with adults, with 
higher morbidity and mortality rates. Pediatric CMPs are also the most 
common cause of heart transplant in children older than one year of age (Lee 
Teresa M. et al, 2017). The cardiomyopathy in children is more often part of a 
metabolic, multi-organ disorder than in adults (El-Hattab and Scaglia, 2016). 
In infants and young children, the presenting symptoms are usually poor 
feeding, growth failure, tachypnea (rapid breathing), hepatomegaly, extreme 
sleepiness, and excessive sweating. In older children, CMPs may manifest 
with abdominal symptoms caused by hepatomegaly and low cardiac output, 
tachypnea, dizziness and fainting, chest pain, and extreme fatigue. Some 
affected children may have no symptoms (Hollander et al, 2013; Kantor et al, 
2013). 
Although there are different classification systems for CMPs [reviewed by 
(McKenna William J. et al, 2017)], the morpho-functional status of the heart 
is a central consideration (Elliott et al, 2008; Rapezzi et al, 2013). Based on 
this criterion, the following main types of CMPs exist (Lipshultz et al, 2013): 
Dilated cardiomyopathy (DCM) is characterized by left ventricular 
dilation, systolic dysfunction, and myocardial fibrosis. The heart muscle 
becomes thin, the left ventricle enlarged, and the heart pumps blood 
insufficiently. At the cardiomyocyte level, impaired generation or 
transmission of force ultimately leads to protein and organelle degradation 
and apoptosis. Approximately 50% of childhood CMPs are dilated, with 10-
25% of them attributed to acute myocarditis (Lipshultz et al, 2003; Towbin et 
al, 2006). In DCM, the five-year transplant-free survival rate ranges from 60-
75%, with most events occurring within the first two years of presentation. 
About 20-45% of patients regain normal cardiac function five years after 
diagnosis [reviewed by (Lee Teresa M. et al, 2017)].  
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Hypertrophic cardiomyopathy (HCM) manifests with left ventricle 
hypertrophy and impaired diastolic function. The hypertrophy can occur at 
the interventricular septum, at the inferior wall, at the apex, or throughout 
the entire left ventricle. When hypertrophy is severe, the muscle can block 
blood flow from the left ventricle to the aorta, condition termed outflow tract 
obstruction. In HCM, the cardiomyocytes appear disorganized and irregular. 
This appearance is called cardiomyocyte disarray and may cause changes in 
the electrical signals traveling through the ventricles leading to ventricular 
arrhythmias (abnormal heart rhythm). Fibrosis can also be observed at the 
tissue level. The hypertrophic form represents 35-50% of total childhood 
CMPs (Arola et al, 1997; Lipshultz et al, 2003; Nugent et al, 2003). The 
survival for pediatric HCM is 97% at five years and 94% at ten years after 
diagnosis. The mortality for HCM peaks before one year of age and again 
between eight and 17 [reviewed by (Lee Teresa M. et al, 2017)]. 
Restrictive cardiomyopathy (RCM) manifests with diastolic dysfunction. 
The heart muscle becomes rigid and unable to relax and fill with blood, 
causing abnormal heart rhythms and heart failure symptoms. RCMs are 
diagnosed in <5% of childhood cardiomyopathies and have notably poor 
outcomes. The five-year transplant-free survival rate is 22% for children with 
pure RCM and 68% for children with an RCM/HCM phenotype (Webber 
Steven A. et al, 2012). 
Hallmarks of left ventricular noncompaction cardiomyopathy (LVNC) 
are trabeculations (networks of muscle fibers) of the left ventricular 
myocardium and left ventricular dysfunction. During development, the 
myocardium resembles a network of muscle fibers. As normal development 
progresses, the fibers become compacted, transforming the heart muscle 
from network-like to smooth and solid. In LVNC, these trabeculations 
typically occur at the apex but can be seen anywhere in the left ventricle. 
LVNC may co-occur with other types of heart muscle disorders (HCM, DCM, 
or RCM). It is estimated to account for ~5% of childhood CMPs, and the 
prognosis differs on the clinical subtype (isolated or in combination). 
LVNC/DCM has the least favorable prognosis, with a 43% five-year rate for 
combined death or transplantation (Jefferies et al, 2015). 
Ventricular arrhythmias and impaired systolic function clinically 
characterize arrhythmogenic ventricular cardiomyopathy (AVC). At the 
tissue level, a fibro-fatty replacement of the myocardium takes place. 
Although AVC is very rare in children, it raises many concerns because 55% 
of AVC pediatric patients experience life-threatening arrhythmias, indication 
for a heart transplant, or (sudden) cardiac death (te Riele et al, 2015). 
Histiocytoid cardiomyopathy (HICM) is another rare cardiac disorder of 
infancy and childhood. It predominantly affects girls younger than two years 
of age (female: male ratio 3:1). Clinically, it manifests as severe cardiac 
arrhythmias or dilated cardiomyopathy. Sudden death is a common 
presentation (Gilbert-Barness, 2004). At the tissue level, HICM is 
characterized by the development of abnormal Purkinje fibers, which 
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interfere with normal cardiac conduction, and by subendocardial, epicardial, 
or valvular yellow nodules. The nodules contain histiocyte-like 
cardiomyocytes, filled with an increased number of normal and abnormal 
mitochondria (Finsterer, 2008). HICM is considered mitochondrial 
cardiomyopathy and is typically fatal (Bates et al, 2012). 
The morpho-functional evaluation of the heart is required for screening, 
diagnosis, risk stratification, prognosis, and treatment. For example, in 
DCM, the degree of ventricular dysfunction and dilation is a predictor of 
death or transplantation (Alvarez Jorge A. et al, 2011). In HCM, septal wall 
thickness is associated with sudden death (Bharucha Tara et al, 2015). 
The morpho-functional assessment is typically accomplished by 
echocardiography, repeated over time to monitor the heart status. cMRI 
(cardiac magnetic resonance imaging) can be further used to refine the 
diagnosis, evaluate the cause (e.g., identify inflammatory processes), assist in 
disease management and risk stratification. cMRI is a very sensitive 
technique for assessing the morphological heart phenotype, functional 
performance, and for tissue characterization (such as fibrotic scar, interstitial 
fibrosis, edema) (Lipshultz Steven E. et al, 2019). There are several cMRI 
techniques. Among them, the most frequently used are T1- and T2-mapping 
and late gadolinium enhancement imaging. 
Late gadolinium enhancement imaging evaluates the increased 
extracellular space in the myocardium, which can be a consequence of 
necrosis, fibrosis, edema, or infiltration. In healthy myocardium, the 
extracellular space is limited, but typically it expands in disease. This 
phenomenon can be visualized with intravenous administered gadolinium, 
which distributes rapidly to the extracellular space, but does not cross the 
healthy plasma membranes. 
In addition to the heart morpho-functional assessment, the clinical 
evaluation of a child with CMP includes searching for an underlying 
metabolic, congenital, or acquired cause. About one-third of children 
diagnosed with CMP presents a metabolic or syndromic disorder (Albakri, 
2019; Kindel et al, 2012). 
First, the medical history is reviewed in detail, including growth and 
development, chronic medical issues, and a three-generation pedigree. This 
evaluation is followed by a comprehensive physical examination, paying 
attention to features that may suggest a genetic syndrome. Further, 
biochemical laboratory tests and genetic testing are essential for an accurate 
diagnosis. This multi-step evaluation is extensive and involves a 






2.5.2. GENETICS OF CARDIOMYOPATHIES 
Cardiomyopathies (CMPs) are mainly genetic in origin and typically 
monogenic, although an oligogenic model of inheritance has been sometimes 
suggested to explain diseases challenging to diagnose. In children, CMPs may 
manifest as isolated muscle disorders or as components of developmental or 
metabolic disorders, making their etiology more diverse comparing with 
adults. 
More than 100 disease genes with all modes of inheritance have been 
found to underlie different types of CMPs. Disease-causing variants affecting 
sarcomeric and cytoskeletal proteins, desmosomes, calcium signaling, 
Ras/MAPK pathway, and mitochondrial proteins have been reported in 
pediatric CMPs (Table 3) (Lee Teresa M. et al, 2017). However, the overall 
spectrum of genetic causes in children presents still many unknowns. 
Autosomal dominant inheritance is the most typical in familial isolated 
CMP types, many caused by mutations in sarcomeric proteins (Morita et al, 
2008). Autosomal recessive inheritance often appears in metabolic disorders 
and others, such as disorders caused by cytoskeletal defects. X-linked and 
mtDNA mutations are also involved in CMPs. Noonan syndrome, caused 
typically by de novo pathogenic variants in the Ras/MAPK pathway, 
constitutes an important fraction of the infantile HCMs, with an ~22% 
mortality rate before one year of age (Wilkinson et al, 2012). 
Neuromuscular, metabolic, mitochondrial, and syndromic causes 
contribute to ~1/3 of childhood CMPs (Cox et al, 2006). In a large cohort 
containing 196 HCM children, 40-50% presented a metabolic or syndromic 
disorder (Lipshultz et al, 2003). HCM caused by inborn errors of metabolism 
has an ~50% mortality rate within two years of diagnosis. In a large study of 
1,731 children with DCM, 8% presented a neuromuscular disorder (Alvarez 
Jorge A. et al, 2011). 
Genetic screening in childhood CMP has become part of the 
comprehensive approach to diagnosis and treatment. However, negative 
family history and a negative genetic test result cannot rule out a genetic 
cause. Small pedigrees, unknown causative genes, de novo genetic variants, 
multiple mutations contributing to disease make the genetic characterization 
difficult. Moreover, locus and allelic heterogeneity are known concepts in 
CMPs, also called variable expression. It refers to the instance when the same 
mutation may lead to different CMP types, different severities, and different 
ages of onset, sometimes even within the same family. Variable penetrance 
has also been described in the dominant CMP, and it refers to the individual 
risk for developing CMP when carrying a known pathogenic variant. Modifier 
genes, multiple pathogenic variants, and environmental factors can 
contribute to the clinical picture. 
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Table 3. Disease genes involved in cardiomyopathies. 
Cellular processes affected by disease genes. Modified after Lee et al, 2017 











ACTC1 Atrial septal defect (AD) Different types of 
CMPs (typically AD, 






MYH7 Myopathies (AD) Different types of 
CMPs (typically AD, 
rarely AR) MYBPC3, MYL2, 
MYL3 
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 DSG2, PKP2  
DSP Carvajal syndrome (AR) 
JUP Naxos disease (AR) 
Intermediate 
filament 




DCM (AD, AR) 
Other cytoskeleton 
components 
VCL  HCM, DCM (AD) 




linked for EMD, AD for 
the other genes) 
DCM (X-linked for 












DCM, HCM, RCM 
(AD, AR) 
CAV3 Limb-girdle muscular 
dystrophy (AD, AR) 
Long QT (AD) 
HCM (AD, AR) 
SGCD Limb-girdle muscular 
dystrophy (AR) 
DCM (AD, AR) 
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CRYAB Myofibrillar myopathy DCM (AD, AR) 
Calcium 
signaling 



























GAA Pompe disease 
(glycogen storage 
disease type II) 
HCM (AR) 
LAMP2 Danon disease (glycogen 
storage disease type IIb) 
HCM, DCM  
(X-linked) 









Systemic disorders HCM, DCM (AR) 
Fatty acid 
metabolism 































AARS2, MTO1, ELAC2 
TSFM 
Systemic disorders HCM (AR) 
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COQ2, COQ4, COQ6, 













Neuromuscular/ neurodegenerative disorders 






FXN Friedreich ataxia  HCM (AR) 
mtDNA – mitochondrial DNA, nDNA – nuclear DNA 
AD – autosomal dominant, AD – autosomal recessive, CMP – Cardiomyopathy, HCM – 
Hypertrophic cardiomyopathy, DCM – Dilated cardiomyopathy, LVNC – Left ventricular 
noncompaction cardiomyopathy, ARV – Arrhythmogenic ventricular cardiomyopathy, HICM 
– Histiocytoid cardiomyopathy, OXPHOS – Oxidative phosphorylation 
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Finding the genetic cause of disease enables the cascade screening of family 
members to identify mutation-positive individuals that require cardiac 
surveillance. However, medical therapy and activity restriction are not 
indicated for children positive for a genetic mutation but without CMP 
morpho-functional features. An exception to this rule is endurance and high-
intensity athletics in desmosomal mutation carriers, as they predispose to the 
progression of AVC (James et al, 2013; Sawant et al, 2016). The high genetic 
heterogeneity of CMPs has been an obstacle for the comprehensive 
characterization of disease genes. NGS, allowing coverage of broad genomic 
regions, opened the possibility to overcome this barrier and has been 
invaluable for discovering new causative genes and variants in recent years 
(Andreasen et al, 2013; Rosenbaum et al, 2020). 
2.5.3. STEM CELLS IN MODELING CARDIAC DISORDERS 
Two intrinsic properties define stem cells: long-term self-renewal and the 
ability to differentiate into other cell types. Long-term self-renewal refers to 
their capacity to replicate themselves and produce other similarly potent cells 
over extended periods or through multiple passages while maintaining an 
undifferentiated state. This property is essential for stem cell pool expansion 
and maintenance. The differentiation refers to their capacity to produce 
different cell types, like cardiomyocytes, neurons, or endothelial cells 
(Chagastelles and Nardi, 2011). 
Based on the developmental stage, we can distinguish two main types: 
embryonic stem cells and adult or somatic stem cells. Embryonic stem cells 
have a role in development [reviewd by (Martello and Smith, 2014)]. In 
contrast, adult stem cells maintain the formed tissues' proper function by 
secreting molecules that support tissue function and by replacing damaged 
cells [reviewd by (Simons and Clevers, 2011)]. 
Embryonic and adult stem cells also differ for their capacity to give rise 
to different lineages, known as potency. From this perspective, embryonic 
stem cells are totipotent, pluripotent, or multipotent, while adult stem cells 
are multipotent, oligopotent, or unipotent (Burgess, 2016). 
Totipotent cells (sometimes called omnipotent) possess the ability to 
differentiate into both embryonic and extra-embryonic tissues. In human 
embryos, all cells from zygote to morula (16-cell stage) are totipotent 
(Balakier and Pedersen, 1982; Tarkowski, 1959). Pluripotent cells have the 
capacity to differentiate into all three primary germ layers (endoderm, 
mesoderm, ectoderm) but cannot contribute to extra-embryonic tissues (e.g., 
placenta) (Gardner, 1968). In development, after the morula stage, the 
embryonic stem cells lose totipotency, and the inner mass cells of the 
blastocyst are pluripotent. These cells propagate indefinitely. 
Further down the potency line, multipotent cells are more limited in 
their differentiation capabilities and ability to divide. They produce multiple, 
but not all, cell lineages in developing embryos or adults. Few examples 
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include hematopoietic stem cells, mesenchymal stem cells, and adult neural 
stem cells. Mesenchymal cardiac-specific stem cells give rise to 
cardiomyocytes, smooth muscle, and endothelial cells [reviewed by (Díez 
Villanueva et al, 2012)]. 
Oligopotent stem cells are found in adult organisms and can differentiate 
into a small number of cell types, typically two. An example is represented by 
the oligopotent stem cells on the eye surface that generate new corneal and 
conjunctival cells (Majo et al, 2008). 
Unipotent stem cells, also known as precursor cells, typically arise from 
multipotent stem cells and differentiate into only one cell type. Stem cells in 
the epithelium that regenerate skin can exemplify them [reviewed by 
(Blanpain et al, 2007)]. 
The accumulation of damage in stem cells causes their functional decline 
and induces age-associated degeneration of tissues (Sharpless and DePinho, 
2007). The potential of stem cell-based therapies for regenerative medicine 
fuelled the stem cell field (De Luca et al, 2019; Trounson and DeWitt, 2016). 
However, the use of human embryonic stem cells (ESCs) in research has been 
challenging due to ethical and legislative considerations regarding their 
human embryonic origin. A brilliant solution to this issue was the 
development of reprogramming strategies to convert somatic cells, like 
fibroblasts, to induced pluripotent stem cells (iPSCs). 
In 2006, Yamanaka and Takahashi used the overexpression of 
transcription factors specific to ESCs to reprogramme mouse fibroblasts to a 
pluripotent state. They determined that a combination of OCT3/4, SOX2, 
KLF4, and c-MYC (OSKM), was enough for robust reprogramming of mouse 
fibroblasts to pluripotency (Takahashi and Yamanaka, 2006). The Japanese 
researchers and their colleagues soon reported the generation of human 
iPSCs using the same strategy, highlighting that OSKM is a bona fide set of 
pluripotency transcription factors (Takahashi et al, 2007). A slightly different 
set of factors containing OCT3/4, SOX2, NANOG, and LIN28 was used by 
Thomson and colleagues to generate iPSCs, with similar efficiencies (Yu et al, 
2007). Nowadays, both sets and their combinations are popular for 
reprogramming somatic cells to pluripotency. iPSCs can be defined as a type 
of pluripotent stem cells generated directly from somatic cells by 
overexpression of a set of early pluripotency transcription factors. 
Human iPSCs-derived cardiomyocytes (iPSC-CMs) have been used to 
model inherited cardiac disorders for investigating pathogenic mechanisms 
(Chen et al, 2016) and to test novel therapeutic agents (Paik et al, 2020). 
Moreover, iPSC-CMs offer a personalized platform to test the cardiotoxicity 
of drugs (e.g., chemotherapy drugs doxorubicin and tyrosine kinase 
inhibitors) (Gintant Gary et al, 2019; Kussauer et al, 2019; Pang, 2020). 
Success in these areas, however, requires iPSC-CMs that recapitulate the 
physiology and pathology of adult cells. The iPSC-CMs generated with 




Adult cardiomyocytes and iPSC-CMs differ in several important ways 
(Musunuru Kiran et al, 2018). One of them is gene expression, adult CMs 
displaying high levels of sarcomeric, calcium handling, and OXPHOS genes. 
In contrast, iPSC-CMs display high levels of MYH6 as opposed to MYH7 and 
other embryonic isoforms (Xu et al, 2009). 
Structurally, adult CMs exhibit a high length-to-width ratio and are more 
often bi-nucleated. Moreover, they present T-tubules at the sarcomere's Z-
lines, ensuring efficient calcium handling and propagation of contraction. 
The sarcomeres are highly organized, with a length of 2.2 μm, and display Z-
discs, I- and A-bands, H-zones, and M-lines. Adult cardiomyocytes are rich 
in mitochondria, which account for ~25% of the cell volume. In contrast, 
immature iPSC-CMs tend to be round, often mono-nucleated, with 
disorganized and shorter sarcomeres of 1.6 μm length. Typically, they do not 
form T-tubules and only have Z-discs and I-bands. Their mitochondrial 
volume is also lower [reviewed in (Yang et al, 2014)]. 
The metabolism of adult cardiomyocytes relies primarily on fatty acid 
oxidation for efficient energy production, with high levels of OXPHOS. 
Although iPSC-CMs possess some capacity to metabolize fatty acids, they rely 
mostly on glucose and lactate (Correia et al, 2017). 
Contractile function in adult cardiomyocytes also varies from iPSC-CMs, 
with adult cardiomyocytes generating greater force and conduction velocities 
when stimulated [reviewed by (Yang et al, 2014)]. 
The immaturity of iPSC-CMs may obscure the patient phenotype in 
disease modeling and may alter drug responses in screenings and toxicity 
tests. Therefore, efforts endeavored to develop methods for rapid and 
consistent maturation of iPSC-CMs, with variable improvements in maturity. 
These methods include (1) biochemical stimulations (fatty acids and 
galactose medium, T3 hormone treatment, microRNA overexpression, 
inhibition of HIF1 alpha and of LDHA, treatment with soluble factors from 
mesenchymal stem cells), (2) physical stimulations (electrical stimulation, 
substrate stiffness modulation), (3) co-culturing (with fibroblasts or 
endothelial cells), (4) as well as more advanced tissue-engineering 
approaches (organoids, heart-on-chip, engineered cardiac tissues) [reviewed 
by (Guo Yuxuan and Pu William T., 2020; Nugraha et al, 2019; Tu Chengyi et 
al, 2018)]. Among the most promising results were obtained by Ronaldson-
Bouchard et al (2018, 2019) with their approach of mechanical and high-
intensity electrical stimulation of human cardiac tissues grown from early-
stage iPSC-CMs. The engineered tissues displayed adult-like expression 
profiles and remarkably organized ultrastructure (Ronaldson-Bouchard et al, 
2018, 2019). These outcomes are promising for late-onset disease modeling 
and small molecule screening in drug discovery and toxicity assays, as 
maturity is necessary for achieving physiological responses. 
Despite the limitations mentioned above, the use of iPSC-CMs enabled 
successful disease modeling of several cardiomyopathy-associated genetic 
defects. A few examples are modeling of Barth syndrome caused by TAZ 
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mutations (Wang et al, 2014), modeling of the Finnish founder mutations in 
MYBPC and TPM1 leading to adult CMPs (Ojala et al, 2015a), and many 
others [reviewed in (Brodehl et al, 2019; Buikema and Wu, 2017)]. 
Interestingly, a recent study also revealed a non-cardiomyocyte contribution 
to heart disease by engineering 3D cardiac microtissues containing healthy 
iPSC-CMs and AVC patient iPSC-cardiac fibroblasts (Giacomelli et al, 2020). 
This approach highlights the role of microenvironmental cues in disease 
development and the importance of adopting more advanced modeling 




The general aim of this work was to investigate the molecular background of 
rare childhood-onset disorders, with patients belonging to two larger projects 
in our lab: Exomit study of mitochondrial-suspected disorders and 
Cardiomyopathy project with severe early-onset patients from the single 
center in Finland performing cardiac transplants. Our specific aims were: 
 
1. To clarify the underlying genetic cause of an uncharacterized, 
progressive leukeoncephalopathy syndrome with sudden deterioration 
of symptoms following a febrile illness and an ovarian malignant 
tumor (Study I). 
 
2. To define the genetic spectrum of severe childhood cardiomyopathies 
in Finland, using a unique cohort representative for the whole country 
with respect to patients considered for cardiac transplant or who 
required inotropic support (Study II). 
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4. PATIENTS AND METHODS 
4.1. ETHICAL CONSIDERATIONS 
An important ethical consideration in studies of childhood disorders is that 
most patients are too young to allow their own informed consent to 
participate in the study. All the samples were taken for diagnostic purposes 
with informed consent from parents and from patients when they were older 
than 10 years of age. 
The Coordinating Ethical Board of Helsinki University Hospital 
approved the study plan for the Exomit project, with the ethical permit 
number 325/13/03/00/2015. The Childhood Cardiomyopathy project's study 
plan was approved by the Child and Adolescent Psychiatry Ethical Board of 
Helsinki University Hospital and received the ethical permit number 
291/13/03/03/2008. 
Patients and family members donated blood for DNA extraction. Besides, 
for functional studies, cells and tissue samples from selected patients and a 
few controls were also obtained from Helsinki University Hospital. 
4.2. STUDY SUBJECTS 
4.2.1. INFANTILE HYPOMYELINATING LEUKOENCEPHALOPATHY 
The patient presented a progressive leukeoncephalopathy syndrome of 
unknown genetic origin. She was recruited to our lab’s Exomit project on the 
genetics of mitochondrial-suspected disorders because of decreased 
OXPHOS CI + CIII activity in muscle biopsy (Table 4). 
Table 4. Mitochondrial respiratory chain activities in skeletal 
muscle relative to citrate synthase activity (nmol O/min/mg 
mitochondrial protein). 
Measurements Patient Controls 
C I+III 50.1 295±91 
C I+III/CS 0.14 0.34 
C II+III 218.5 276±97 





At the beginning of this project, only samples from the patient were available, 
but not from any other family member, and the latter were not obtained 
either retrospectively. 
4.2.2. CHILDHOOD-ONSET CARDIOMYOPATHY (KIDCMP COHORT) 
The KidCMP was collected by the effort of pediatric cardiologists and 
consisted of 66 unrelated childhood CMP patients who visited between 1993 
and 2014 the Pediatric Cardiology Department of the Helsinki University 
Central Hospital. The cohort included patients younger than 15 years at 
presentation, the majority of Finnish ancestry. 
In Finland, all the invasive and pretransplantation investigations are 
performed in Helsinki for the whole country. The patient inclusion criteria 
were childhood-onset cardiomyopathy with or without other organ systems 
involvement, who came for inotropic support, invasive hemodynamic 
examinations, or pretransplantation evaluation. Exclusion criteria were 
congenital heart disease, arrhythmia-induced cardiac dysfunction, Kawasaki 
disease, ALCAPA (anomalous origin of left coronary arising from pulmonary 
artery), secondary cardiac dysfunction resulting from abnormalities in other 
organs, and maternal diabetes for infants who presented with septal 
hypertrophy before four weeks of age. According to the Declaration of 
Helsinki, informed consent was received from patients when they were older 
than 10 years of age and from parents. Cardiac examinations, including 
echocardiography, were performed for all first-degree relatives and other 
family members. 
Table 4. Mitochondrial respiratory chain activities in skeletal 
muscle (Continuation) 
Measurements Patient Controls 
C II 77.8 181±54 
C II/CS 0.21 0.21 
C IV 1119.4 2620±858 
C IV/CS 3.09 3.05 
Citrate synthase 362.0 858 ± 268 
O = atomic oxygen, C I+III (NADH:cyt C reductase),  C II+III 
(succinate:cyt C reductase),  C II (SDH), C IV (COX), CS= citrate 
synthase, NADH = reduced nicotinamide adenine dinucleotide, Cyt c 
= Cytochrome c, SDH = succinate dehydrogenase, COX 0 
cytochrome c oxidase. 
Patients and methods 
53 
4.3. NEXT-GENERATION SEQUENCING 
4.3.1. TARGETED PANELS 
The first goal of any NGS study is to obtain a high-quality map of genetic 
variation for the investigated samples. This represents the foundation for all 
downstream analyses because variants that are not accurately genotyped 
cannot be directly assessed. Panels offer the advantage of obtaining a very 
accurate map across known disease genes, making them an attractive first 
step in the genetic investigation of many rare disorders. 
We utilized two targeted sequencing panels. CMP-Custom 
HaloPlex Panel (Agilent Technologies), of 117 cardiac genes, was applied to 
32 patients. Pan Cardiomyopathy v1.0 Panel (Blueprint Genetics), of 101 
cardiomyopathy-related genes, was applied to 29 patients. The data obtained 
with the CMP-Custom Haloplex panel were processed using the 
bioinformatic pipeline of the Finnish Institute for Molecular Medicine FIMM 
(Sulonen et al, 2011). The data obtained with the Pan Cardiomyopathy panel 
were processed at Blueprint Genetics with their customized bioinformatic 
pipeline. 
4.3.2. WHOLE-EXOME SEQUENCING 
We sequenced the whole exome of >40 patients, using two service providers: 
the Finnish Institute for Molecular Medicine FIMM (with NimbleGen 
SeqCap EZ Exome v2.0 kit) and the BGI company (with Agilent SureSelect 
Human All Exon v6 kit). Ten patients have been screened with multiple NGS 
methods. Typically, we analyzed only the index patients, except for 3 
families, where additional family members have been included. The whole-
exome sequencing data were processed using FIMM's bioinformatic pipeline 
(Sulonen et al, 2011), with a few recent updates. 
4.4. IDENTIFICATION OF PUTATIVE DISEASE-CAUSING 
VARIANTS 
4.4.1. IN SILICO APPROACHES: VARIANT FILTERING, POPULATION 
DATABASES, PATHOGENICITY PREDICTIONS, 
CONSERVATION IN SPECIES, MOLECULAR MODELING 
The filtering steps and prioritization of SNVs and indels to identify the likely 
pathogenic variants included (Figure 4): 1) selection of rare variants with a 
MAF<0.01 in public databases: ExAC http://exac.broadinstitute.org/ 
gnomAD http://gnomad.broadinstitute.org/, and the Finnish SISu 
http://www.sisuproject.fi/; 2) for a dominant inheritance, the occurrence 
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was not allowed in public databases, while for recessive inheritance only 
heterozygotes were permitted; 3) prediction of variants' deleteriousness 
based on CADD C-score (Kircher et al, 2014), SIFT (Sim et al, 2012), and 
PolyPhen-2 (Adzhubei et al, 2010); 4) further prioritization considered the 
protein function related to patient's phenotype and the amino acid 
conservation in species. 
 
Figure 4. Variant prioritization strategy. Steps in NGS data 
filtering for SNVs (single nucleotide variants) and indels (insertion-
deletions) to identify the likely causative variants. 
 
For interpretation of sequence variants, we followed the guidelines of the 
American College of Medical Genetics and Genomics (ACMG) (Richards et al, 
2015). Variants were considered disease-causing if they met criteria for 
'pathogenic' or 'likely pathogenic' in ACMG classification. In short, the 
causative variants were: 1) known to cause CMP, 2) new variants in genes 
that were relevant for cardiac function, segregated with disease in families, 
were absent in control databases if dominant, or present only as 
heterozygotes if recessive, and altered an evolutionarily conserved amino 
acid in the protein, 3) de novo variants in known CMP genes showing 
multiple bioinformatic evidence of deleteriousness. 
We modeled the consequences of selected variants using the software 
Discovery Studio 4.5 (Biovia) and as templates either the protein crystal 
structures from PDB (Protein Data Bank, https://www.rcsb.org/) or 
homology models deposited at SwissProt (https://www.expasy.org/). The 
program is set to generate 5 mutant models, which typically are very similar, 
and the model with the lowest energy is chosen as representative. 
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4.4.2. FAMILY SCREENING: SEGREGATION, FINGERPRINT 
ANALYSIS 
We verified the putative pathogenic variants by Sanger sequencing and their 
co-segregation with the disease in families. De novo variants, determined by 
being absent in the parents' samples, were further confirmed by DNA 
fingerprinting of patients and parents with seven microsatellite markers. 
Both Sanger dideoxy reactions and the fragment amplification in 
microsatellite analysis were prepared in our lab and submitted to the FIMM 
Sequencing Lab for analysis through capillary electrophoresis. 
4.5. FUNCTIONAL VALIDATION OF DISEASE-CAUSING 
VARIANTS 
4.5.1. PROTEIN ANALYSES: SDS-PAGE, NATIVE-PAGE, WESTERN 
BLOTTING, UNTARGETED PROTEOMICS 
In our projects, we used proteins extracted from cultured fibroblasts and 
skeletal muscle biopsies. 
To extract proteins for SDS-PAGE, the cultured fibroblasts were collected 
by trypsinization, total cellular proteins extracted in RIPA buffer 
(Radioimmunoprecipitation assay buffer: 50 mM Tris-Cl pH8, 150 mM NaCl, 
1% TritonX 100, 0.5% sodium deoxycholate, 0.1% SDS) containing protease 
and phosphatase inhibitors, and quantified by Bradford method. From 
tissues stored at -80°C, a small piece was cut in a jar kept on dry ice and 
quickly homogenized in cold PBS containing protease and phosphatase 
inhibitors. 5x RIPA buffer was quickly added to a final concentration of 1x. 
The samples were further extracted by incubating for 20 minutes on ice, 
followed by 20 minutes centrifugation at 20.000xg to pellet the debris. 
Protein concentration was determined with BCA Pierce Kit (Thermo Fisher). 
The proteins were separated on 4-20% Mini-Protean TGX Stain-FreeTM 
gels (Bio-Rad) and transferred to 0.2 μm PVDF (polyvinylidene fluoride) 
membranes for Western blotting using the Trans-Blot TurboTM Transfer 
System (Bio-Rad). The blots were blocked in 5% milk in TBS-Tween 20 
(0.1%), incubated overnight with a primary antibody, and followed by one-
hour incubation the next day with an HRP-conjugated secondary antibody. 
The chemiluminescent reaction was used to develop the signal that was 
finally captured with Bio-Rad ChemiDoc™ XRS+ imager. 
Proteomics analysis used the same tissue samples extracted in RIPA 
buffer as described above. For accurate quantification, the lysates were 
measured three independent times with BCA Pierce Kit (each time with two 
technical repeats). The protein concentration was determined as the average 
value of all measurements. The extracted proteins were further purified to 
remove detergents, and a small amount of each sample was used for 
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untargeted mass spectrometry. The data were analyzed using GraphPad 
Prism 8. 
Native-PAGE enabled the isolation of intact mitochondrial complexes. 
We followed a protocol described approximately 30 years ago (Schägger and 
von Jagow, 1991), with a few adjustments. The purpose was to evaluate the 
integrity of mitochondrial complexes in primary fibroblasts from our patients 
with PPA2 genetic defect compared to control fibroblasts. The fibroblasts 
were grown in DMEM medium without glucose (Thermo Fisher) 
supplemented with 1o% FBS, 1x GlutaMAX (Gibco), antibiotics 1x Pen Strep 
(Gibco), 10 mM D-galactose (Sigma-Aldrich), and 50 μg/ml uridine. When 
the plate was 90% confluent, the cells were pelleted by centrifugation and 
resuspended in cold PBS containing protease inhibitors. Further, all the steps 
were carried out on ice or at +4°C. First, the cells received a digitonin 
solution, which disrupted the plasma membrane and the outer mitochondrial 
membrane. Cell lysates were centrifuged at 10,000xg for 10 minutes, and the 
supernatant was removed. The pellets, containing mitochondria, received a 
further treatment with lauryl maltoside solution, which released 
mitochondrial complexes from the inner membrane. After centrifugation at 
20,000xg for 20 minutes, the collected supernatant contained the desired 
protein complexes. After quantification, 10 µg of proteins were separated on 
a native-PAGE gel (NuPAGE Bis-Tris, Invitrogen). The proteins were further 
transferred from the gel to a PVDF membrane, which was used in Western 
blotting, as described above. 
4.5.2. EXPRESSION ANALYSIS 
Total RNA was isolated from fibroblasts, heart biopsies, and iPSCs using the 
RNeasy Mini kit (Qiagen). The cDNA was generated from 0.3-1 µg RNA using 
Maxima First Strand cDNA Synthesis Kit with dsDNase (Thermo Scientific). 
All qPCR reactions were performed in triplicate, using either IQTM SYBR 
Green Supermix (Bio-Rad) or SensiFASTTM SYBR (Bioline). 
4.5.3. VISUALIZATION OF CELLULAR STRUCTURES BY 
IMMUNOFLUORESCENCE 
Immunofluorescence is a very versatile technique, and we employed it with 
different types of cells: fibroblasts, U2OS cells, iPSCs, iPSC-CMs. 
The fibroblasts and U2OS cells were fixed in 4% PFA in PBS for 15 
minutes, followed by three washes with PBS. iPSCs and cardiomyocytes were 
prefixed for 10 minutes by adding an equal volume of 4% PFA to their 
medium, followed by 10 minutes fixation with 4% PFA, and three washes 
with PBS. A subset of cardiomyocytes was fixed after preincubation with a 
'relaxing buffer' to distend the sarcomeres. The relaxing buffer consisted of 
150 mM KCl, 5 mM MgCl2, 10 mM MOPS, 1 mM EGTA, adjusted to pH 7.4, 
and 4mM ATP freshly added. 
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The fixed cells were kept at +4°C in PBS until were stained (or in PBS 
with 0.02% sodium azide if they were stored longer). For staining, the cells 
were first permeabilized for 15 minutes using 0.2% TritonX-100 in PBS, 
washed with PBS, followed by a blocking step of 1 hour with 10% horse 
serum, 1% BSA, and 0.1% TritonX-100 in PBS. The cells were washed once 
with 1% horse serum, 1% BSA, and 0.1% TritonX-100 in PBS and incubated 
with primary antibodies overnight at +4°C. The primary antibodies were 
diluted in 1% horse serum, 1% BSA, and 0.1% TritonX-100 in PBS. The next 
day, the cells were washed three times with 1% BSA in PBS and incubated 
with secondary antibody, or with phalloidin (to stain F-actin) plus secondary 
antibody diluted in 1% BSA in PBS. The final washes were three times with 
PBS and one time with PB. We mounted the coverslips on glass using 
Vectashield Mounting Medium with DAPI (Vector Laboratories). 
4.5.4. DISEASE MODELING USING INDUCED PLURIPOTENT STEM 
CELL (IPSC)-DERIVED CARDIOMYOCYTES 
4.5.4.1. Generation and characterization of iPSCs 
The reprogramming process unfolds in two broad phases (Polo et al, 2012; 
Theunissen and Jaenisch, 2014). (1) The early reprogramming phase, 
characterized by stochastic binding of OSKM (Oct3/4, Sox2, Klf4, and c-Myc) 
to their target promoters in the genome. OSKM components possess pioneer 
transcription factor activity, binding to inaccessible chromatin areas where 
they remodel the epigenetic markers, thus modifying gene expression. The 
consequence of epigenetic remodeling is the induction of early pluripotency 
genes and the repression of somatic cell transcription programs. (2) The 
reprogramming late phase is more deterministic, distinguished by a gradual 
activation of the late pluripotency genes and the establishment of full 
pluripotency by endogenous gene regulatory networks. 
We used low-passaged primary fibroblasts to obtain iPSCs from 
patient and control lines. Neon electroporation system was used to transduce 
700,000 cells with three plasmids containing Yamanaka factors OSKM: 
pCXLE-hOCT3/4-shp53-F, pCXLE-hSK, and pCXLE-hMLN (1 µg each). We 
used 1,650V, 10 ms, and 3 pulses for electroporation, after which the cells 
were transferred into 6-cm freshly gelatinized dishes (0.15% gelatin) 
containing warm fibroblast medium. We considered this day 1. The medium 
was changed to cells on days 2 and 4. On day 5, we prepared feeder plates for 
passaging the cells by seeding ~20,000 mitotically inactivated MEFs (mouse 
embryonic fibroblasts) per freshly gelatinized 6-cm dishes and cultured them 
overnight in fibroblast medium. On day 6, the electroporated cells were 
collected with TrypLETM Express (Gibco), pelleted by centrifugation, 
resuspended in fibroblast medium, and seeded at 150,000-300,000 cells/6-
cm feeder plates. The feeder layers of mitotically inactivated MEFs secrete 
 
58 
growth factors and provide a good surface for culture. More recent 
techniques grow the electroporated cells directly on matrigel to avoid feeder 
contamination and mechanical cutting. On day 7, we changed to hES 
medium, which was refreshed every second day afterward. hES medium 
promotes pluripotency and contains DMEM/F12 with Glutamine (Life 
Technologies), 20% KnockOut Serum Replacement (Gibco), 0.0915 mM 2-
βMercaptoethanol (Sigma-Aldrich), 1x Non-essential amino-acids (Gibco), 
6ng/ml recombinant human FGF basic (Peprotech), and 0.25 mM Sodium 
butyrate (MilliporeSigmaTM). Around day 20, iPSC foci may become ready for 
cutting. We cut the colonies mechanically using a scalpel and plated them on 
freshly gelatinized 4-well dishes with feeder cells and hES medium. A few 
initial passages were done by mechanical cutting with a scalpel, on feeder 
cells with hES medium. Afterward, the cells were transferred on matrigel-
coated plates and cultured further in E8 medium (Essential 8TM Basal 
Medium plus 1x Essential 8TM Supplement, Gibco) until they displayed the 
characteristic morphology of tightly packed colonies with defined borders. 
iPS cells are small (~43.5 µm in size), with a small cytoplasm around the 
nucleus (~0.87 nucleus to cytoplasm ratio). The colonies grow in a single 
layer and present a cell density of ~6,000/mm2 (Wakao et al, 2012). The E8 
medium contains only 8 elements, including the growth factors TGFB1 and 
FGF2. The matrigel is a substitute for extracellular matrix, providing cell 
attachment and promoting survival. iPSCs are particularly sensitive to single-
cell dissociation, quickly triggering apoptosis when cells lose any contact, a 
process termed anoikis (Gilmore, 2005). The addition of Rock inhibitor 
(Y27632) promotes quick attachment to a coated surface and substantially 
improves survival. 
For passage, the cells were washed once with PBS, after which they 
were incubated with 0.5 mM EDTA for about 5 minutes at room 
temperature. The EDTA was aspirated gently, and fresh E8 medium was 
added to the dish to resuspend the cells, which were distributed to new 
plates. To freeze the cells, we followed the same procedure as above but 
resuspended the cells in ice-cold FBS with 10% dimethyl sulfoxide and added 
them to a cryovial cooled on ice. The patient and control iPSCs were 
expanded over passage 30, with cells frozen as stocks at different passages. 
Several markers of pluripotency were tested at the protein and mRNA 
levels. At the protein level, we tested the surface markers SSEA4 and TRA-1-
60, and the nuclear transcription factor NANOG. 
4.5.4.2. Cardiomyocyte differentiation, maturation, and 
characterization 
For cardiomyocyte differentiation, we followed the small molecule protocol 
(Burridge et al, 2015), with a few modifications. The iPSCs were grown on 
matrigel (Corning) in E8 medium for 3-4 days until they became 65-85% 
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confluent. At this stage, they were dissociated to single cells by incubating 
them for 7 minutes with 0.5 mM EDTA in PBS. Further, we seeded 120,000 
cells/well of a 6-well dish coated with growth factor reduced matrigel 
(Corning) in the presence of 10 µM Rock inhibitor (Y27632). The E8 medium 
was changed regularly until cells reached confluence, and the differentiation 
process was started. We used for induction CDM3 glucose medium with 3-
4.5 µM CHIR99021 (Sigma-Aldrich), a GSK3B (Glycogen synthase kinase 3 
beta) inhibitor that mediates epithelial to mesenchymal transition. CDM3 
glucose medium consisted of RPMI 1640 with glucose and L-glutamine 
(Gibco) supplemented with 75 mg/ml human recombinant albumin (Sigma-
Aldrich) and 64 mg/ml L-ascorbic acid 2-phosphate (Sigma-Aldrich). After 48 
h, the cells were washed with PBS, and the medium was changed with CDM3 
glucose containing 2 µM Wnt-C59, an inhibitor of the WNT pathway. After 
another 48 h, the cells were washed, and the medium was changed with 
normal CDM3 glucose and refreshed every other day from this point. The 
cells typically started to beat between days 7 and 10. 
We replated the cells on day 20 at a higher density of 1-1.5 million 
cells/well of a 24-well plate coated with matrigel. We used the Multi Tissue 
Dissociation Kit 3 (Miltenyi Biotech) for cardiomyocyte dissociation, and for 
purification, we used PSC-Derived Cardiomyocyte Isolation Kit (Miltenyi 
Biotech). Finally, the enriched cells were collected in 15 ml tubes topped with 
CDM3 medium and 20% FBS. The cells were pelleted at 500xg for 5 minutes, 
resuspended in 1 ml CDM3 containing 20% FBS, and 10 µM Rock inhibitor 
(Y27632), counted, and seeded. The cells started to contract after 2-5 days. 
At day 30 of culturing in CDM3 glucose medium, we began the 
maturation of cells by switching to CDM3 galactose and fatty acids. The 
CDM3 galactose and fatty acids medium consisted of RPMI 1640 without 
glucose but with L-glutamine (Gibco), supplemented with 75 mg/ml human 
recombinant albumin (Sigma-Aldrich), 64 mg/ml L-ascorbic acid 2-
phosphate (Sigma-Aldrich), 0.025% glucose (Gibco), 7.5 mM D-galactose 
(Sigma-Aldrich), 100 µM oleic acid-albumin (Sigma-Aldrich), 50 µM sodium 
palmitate (Sigma-Aldrich), and 100 µM L-carnitine (Sigma-Aldrich). The 
maturation continued for 15 days. Around day 45, the cardiomyocytes were 
dissociated and replated on matrigel-coated coverslips for 
immunofluorescence staining. The seeding density was about 125,000 
cells/well of a 24-well plate for immunofluorescence. The cells were fixed 
with PFA 4%, 3-4 days after replating (detailed above at immunofluorescence 
method). The purity of cardiomyocyte cultures was assessed by 
immunofluorescence using cardiac troponin T (cTnT) as marker. iPSC-CM 
cultures from Patient 1 and Control 1 presented >80% purity. 
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5. RESULTS AND DISCUSSION 
5.1. HEAT SHOCK RESPONSE IS A NOVEL DISEASE 
MECHANISM UNDERLYING INFANTILE 
LEUKOENCEPHALOPATHY (STUDY I) 
5.1.1. CLINICAL PRESENTATION 
The patient was a girl, the first child of a healthy Finnish couple with two 
younger healthy sons. The parents were distantly related. From birth, she 
was irritable and presented an increased muscle tone. In the next two years, 
she was diagnosed with delayed motor development and other symptoms 
common to white matter disorders. The remarkable feature of her disease 
was a sudden and dramatic deterioration following a febrile illness at two 
years and three months, with an encephalitis-like episode, prolonged 
seizures, and unconsciousness. She was treated in an intensive care unit for 
four days with antiepileptic, antiviral, and antibiotic medication, but no 
bacteria, virus, or antibodies could be detected. Another particularity of her 
disease was a malignant ovarian tumor diagnosed at six years of age and 
treated with chemotherapy. Her disease was progressive and the diagnostic 
based on MRI at ten years of age was hypomyelinated leukoencephalopathy 
with periventricular cysts and atrophy of the cerebellar vermis. At 15 years of 
age, she died of pneumonia. 
5.1.2. IDENTIFICATION OF HIKESHI MUTATION 
The WES data of our patient was filtered first to detect a probable 
homozygous mutation. After applying the filtering criteria (consisting of 
homozygosity, allele frequency <0.01 in Finnish cohorts and ExAC, CADD C-
score >10, call depth >10, and absence of homozygotes in ExAC), one 
homozygous variant was found, which seemed the most likely cause of the 
patient’s disease: HIKESHI, c.11G>C, p.Cys4Ser. 
The variant was not present in the population database ExAC, which 
included exome data from more than 3,000 Finns, and was predicted to be 
deleterious by SIFT and CADD (the C-score was 20.7). The variant causes a 
missense mutation, exchanging a conserved cysteine to serine (p.Cys4Ser) in 
the protein's N-terminus. 
The function of the protein Hikeshi was characterized in 2012 as the only 
transporter of HSP70s into the nucleus during heat stress (Kose et al, 2012). 
A few years later, a founder mutation in the HIKESHI gene (p.Val54Leu) was 
described to cause leukoencephalopathy with acquired microcephaly in 
Ashkenazi-Jewish (AJ) families (Edvardson et al, 2016). The name of the 
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gene and protein, Hikeshi, is a Japanese word for firefighter, reflecting its 
role in protecting cells from heat shock stress (Rahman et al, 2017). This 
function is achieved through the binding and nuclear transport of HSP70s, a 
major class of heat shock proteins (HSPs) (Figure 5).  
The function of HSP70s relates to protection against stress and 
maintenance of homeostasis by promoting protein folding and refolding, 
proteasome-dependent degradation, chaperone-mediated autophagy, and 
protection against inclusion formation. The HSP70s’ numerous functions 
affect almost all aspects of protein life cycle, from synthesis to degradation 




Figure 5. Cellular function of Hikeshi during heat stress. 
(A) Functional Hikeshi is an asymmetric homodimer. All domains of 
Hiheshi seem to be essential for HSP70 binding. (B) During heat shock, 
Hikeshi binds HSP70s and transports them into the nucleus, where 
HSP70s assist in client protein folding. 
 
Our study was the second report of HIKESHI mutations, expanded the 
disorder's clinical phenotype, and added knowledge to cellular pathways 
contributing to disease. 
5.1.3. REMODELING OF INTERACTIONS INSIDE THE HYDROPHOBIC 
POCKETS OF HIKESHI LEADS TO PROTEIN INSTABILITY 
The functional Hikeshi is an asymmetric homodimer, and its asymmetry is 
important for HSP70 binding (Song et al, 2015). Each monomer consists of 
an N-terminal domain (NTD) folded into a jelly-roll/β-sandwich structure 
and a C-terminal domain (CTD) with a coiled-coil-like conformation, which 
are connected by a flexible linker region (Figure 6A). 
The NTDs contain the hydrophobic pockets involved in FG-Nups 
(phenylalanine-glycine repeat-containing nucleoporins) recognition. The 
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interaction between Hikeshi and FG-nups is proposed to be regulated by a 
flexible extended loop (E-loop) in the NTD. The E-loop covers the 
hydrophobic pocket like a lid. One amino acid in the E-loop, Phe97, 
protrudes into the hydrophobic pocket, playing a critical role in closing and 
opening the lid (Figure 6B). The open conformation enables binding to FG-
nups, allowing further the translocation into the nucleus. 
The amino acids altered in the Finnish and AJ patients, Cys4 and Val54, 
respectively, are localized within the NTDs and are involved in hydrophobic 
interactions inside the pockets. 
 
 
Figure 6. Structure of Hikeshi after Song et al, 2015. 
(A) The N-terminal domain of Hikeshi contains the hydrophobic pocket, 
which is covered by the E-loop. Upon binding, the E-loop modifies its 
conformation to expose the hydrophobic pocket involved in nuclear pore 
recognition. (B) Phe97 protrudes into the N-terminal domain's 
hydrophobic pocket, playing an important role in covering or exposing the 
surface involved in FG-Nups recognition. 
 
The wild type Cys4 establishes two hydrophobic interactions in both 
monomers, with Phe25 and Ile111. Computational modeling of p.Cys4Ser 
mutation indicated that the missense change would determine the loss of the 
hydrophobic bonds in both monomers. In monomer A, the side chain of Ser4 
would form a new hydrogen interaction with the aromatic ring of Phe25, 
while in monomer B, Ser4 establishes no interactions. Therefore, the 
hydrophobic interactions inside the pockets are altered and weaker for 
p.Cys4Ser mutation. Western blot showed undetectable levels of Hikeshi in 
patient fibroblasts, consistent with the idea that altered interactions inside 
hydrophobic pockets induce protein instability. 
Edvardson and colleagues (2016) also showed an undetectable level of 
protein in Western blot for the AJ founder mutation p.Val54Leu; therefore, 
we also analyzed the AJ missense change by computational modeling. An 
asymmetry in hydrophobic interactions inside the two monomers' pockets is 
observed for the wild type Val54, which establishes three hydrophobic 
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interactions in monomer A, with Val38, Phe82, and Ile113, but only two in 
monomer B, with Val38 and Phe82. In the model of p.Val54Leu mutation, 
Leu54 forms four hydrophobic bonds in both monomers, with Val38, Val 73, 
Phe82, and Ile113. We observe, thus, the loss of binding asymmetry between 
the two monomers characteristic for the wild type Val54 and remodeling of 
hydrophobic interactions inside the pockets, which become stronger with 
Leu54 mutation. 
The dramatic conformational changes undergone by Hikeshi upon 
HSP70 binding require a structure with a high degree of flexibility, which 
maintains at the same time the ability to bind to FG-nups and translocate 
into the nucleus. The observation that both decreased and enhanced 
hydrophobic interactions inside the pockets would lead to protein instability 
suggests that the pockets' 3D conformation is under functional constraints 
and cannot tolerate significant alterations without affecting stability. 
5.1.4. HIKESHI DISEASE MECHANISM INVOLVES BOTH NUCLEAR 
CHAPERONE AND ER FUNCTIONS 
During heat shock, the expression of HSP70s increases, and they translocate 
into the nucleus to protect nuclear structures from heat damage. The damage 
refers to the loss of native conformation of proteins (associated with DNA, 
RNA, or carrying out other tasks) inside the nucleus (Imamoto and Kose, 
2012). After one-hour heat shock at 42°C, control fibroblasts exhibit a 
substantial punctate accumulation of HSP70 inside the nucleus, while the 
patient's fibroblasts carrying the p.Cys4Ser mutation show weaker 
accumulation. However, variability characterized the repeats of this 
experiment. Therefore, we suggest that other factors might modulate HSP70s 
transport into the nucleus during heat shock, possibly on a cell-type-specific 
basis. Both patient and control fibroblasts responded to heat shock by 
phosphorylating HSF1-S326. 
Given that heat shock and endoplasmic reticulum (ER) stress responses 
have common mediators, we screened the ER stress markers in the patient's 
cells. HikeshiCys4Ser fibroblasts showed normal levels of unfolded protein 
response (UPR) markers IRE1α and BiP. These markers also show a typical 
upregulation pattern when patient cells were treated with the ER stressor 
tunicamycin. Interestingly, we found that the level of ERO1-Lα, an ER 
oxidoreductase, was markedly reduced in the patient's fibroblasts. Therefore, 
we can state that ERO1-Lα reduction was independent of a generalized 
activation of ER-UPR or defective ER-UPR expression. 
5.1.5. HEAT SHOCK RESPONSE IN MYELIN DISORDERS 
As discussed in the introduction, leukoencephalopathies can result from 
genetic defects in many cellular pathways. Among them, we encounter 
pathways related to nucleic acid metabolism, immunity to nucleic acids, 
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protein quality control, and ER stress, which are all vulnerable pathways in 
Hikeshi disorder. 
The inefficient nuclear import of HSP70s in patients' cells will likely 
render the nucleus vulnerable to protein and nucleic acid damage and 
supports the idea that an inadequate response to heat stress is an essential 
element of the Hikeshi disorder mechanism. The nuclear transport of 
HSP70s by Hikeshi has been mostly studied in the context of heat stress 
(Imamoto, 2018). It would be interesting to address the question if other 
types of cellular stress would affect the Hikeshi pathway. 
At the age of two years and three months, our patient manifested 
pronounced deterioration following a febrile illness with suspected 
encephalitis. In this context, it is noteworthy that three out of six AJ patients 
died suddenly during short febrile illnesses, implying abnormal responses to 
heat stress. Moreover, our patient was diagnosed with a malignant ovarian 
tumor. Although, as a single finding, this can be coincidental, cellular stress 
responses mitigated by heat shock proteins have been described in both 
neurodegenerative disorders and cancer (Lindberg et al, 2015; Sherman and 
Gabai, 2015). 
A rising question concerns the downstream effects of heat shock damage 
and how the cells respond to nuclear stress. One proposed hypothesis is that 
the excess of extra-nuclear HSP70s might initiate cytokine release or provide 
a target for natural killer cells (Edvardson et al, 2016). An alternative to this 
explanation would be an activation of the innate immune system by altered 
DNA and RNA metabolism during heat shock, or other types of cellular 
stress, in patients with Hikeshi mutations. Innate immunity activation 
induced by disrupted nucleic acid metabolism has been illustrated by another 
demyelinating syndrome, Aicardi-Goutières (Blumen et al, 2012; Rice et al, 
2007). 
The synthesis and turnover of plasma membrane components are 
accomplished through the secretory pathway. This pathway becomes 
particularly active in myelinating cells, which have to synthesize and deliver 
considerable amounts of membrane proteins, cholesterol, and other 
membrane lipids to specific membrane sites. Endoplasmic reticulum (ER) 
stress disrupts the secretory pathway, and ER unfolded protein response 
(UPR) appeared as a recurrent theme in myelin disorders as in Pelizaeus-
Merzbacher disease, vanishing white matter disease, Charcot-Marie-Tooth, 
and multiple sclerosis (Lin and Popko, 2009). We found normal levels of ER-
UPR markers in the patient’s cells, markers that were also normally 
upregulated during tunicamycin treatment. However, we uncovered a clear 
reduction of ERO1-Lα, an ER oxidoreductase involved in disulfide bond 
formation and ER redox state, indicating that ER likely contributes to the 
cellular pathology of Hikeshi disorders. 
The major function of HSPs is to ensure proper folding and prevent 
protein aggregates, with HSP70s being involved in the active folding and 
refolding of proteins. Only a few examples of other genes encoding 
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chaperones and co-chaperones causing diseases with nervous system 
involvement are HSPD1 in hypomyelinating leukodystrophy (Magen et al, 
2008) and hereditary spastic paraplegia (Hansen et al, 2002); TBCE causes 
Sanjad-Sakati and Kenny-Caffey syndromes (Parvari et al, 2002); SIL1 leads 
to Marinesco-Sjögren syndrome (Anttonen et al, 2005; Senderek et al, 
2005); DNAJC6 (Edvardson et al, 2012) and DNAJC13 (Vilariño-Güell et al, 
2014) are involved in Parkinson’s disease; DNAJC19 in dilated 
cardiomyopathy with ataxia (Davey et al, 2006; Ojala et al, 2012a). The 
addition of HIKESHI to this list highlights the crucial role of adequate stress 
responses in the nervous system's normal development and maintenance. 
5.2. GENETIC LANDSCAPE OF SEVERE CHILDHOOD 
CARDIOMYOPATHIES IN FINLAND (STUDY II) 
5.2.1. THE CHARACTERISTICS OF KIDCMP COHORT 
REPRESENTATIVE FOR FINLAND FOR SEVERE CHILDHOOD 
CARDIOMYOPATHIES 
The childhood cardiomyopathy (CMP) genetics project started in our lab 
many years back by dedicated clinicians who have gathered clinical 
information and biological samples from patients and family members. With 
centralized data and support for research, the Finnish medical system has 
played a key role in our project, facilitating the cohort collection. In Finland, 
all severe pediatric cardiomyopathy patients that require inotropic support or 
are evaluated for cardiac transplant are investigated at University Hospital in 
Helsinki. This provided us the unique opportunity to collect the KidCMP 
cohort, representing the whole country for this subgroup of severe childhood 
cardiomyopathy patients. As most of the patients did not have a genetic 
diagnosis at the study initiation, the cohort was considered naïve from a 
genetic perspective. 
The KidCMP cohort consists of 66 patients and presents three 
characteristics that are making it unique: a) mostly based on Finnish 
ancestry, with a history of geopolitical isolation and genetic homogeneity; b) 
early-onset, with a median diagnosis age of 0.33 years (mean 2.05 years); c) 
representative of severe childhood cardiomyopathy diversity of a country, as 
it was collected from the single center in Finland performing cardiac 
transplantations. 
There were five CMP types in the cohort: dilated cardiomyopathy (DCM, 
n=37), hypertrophic cardiomyopathy (HCM, n=20), left ventricular 
noncompaction (LVNC, n=6), restrictive cardiomyopathy (RCM, n=2), and 
histiocytoid cardiomyopathy (HICM, n=1). Seventeen patients underwent 
cardiac transplantation, 18 have died of their disorder, the cardiac findings in 
14 patients were stabilized with treatment, and 17 present a progressive 
disorder. For the 17 transplanted and 18 deceased patients, the average 
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transplant time was 1.97 years (median 1 year), and the average death time 
occurred 2.24 years (median 0.315 years) after the initial diagnosis. 
Forty-three patients were females, 23 males (a trend towards female 
preponderance). Of all, 49 had no familial history, suggesting an autosomal 
recessive inheritance or de novo occurrence. Seventeen patients showed a 
familial disease: in 7 families with multiple affected siblings and healthy 
parents, we considered recessive inheritance, while 10 families showed 
dominant inheritance. 
5.2.2. HETEROGENEOUS GENETIC BACKGROUND ENRICHED IN DE 
NOVO MUTATIONS 
Our lab has been a pioneer in Finland for using NGS for the genetic diagnosis 
of cardiomyopathies, with the publication of AARS2 as a novel disease gene 
underlying fatal neonatal CMP (Götz et al, 2011). Other publications 
followed, including MRPL44 as a novel disease gene (Carroll et al, 2013) 
discovered by WES, and a few clinical reports on PRKAG2 and HRAS 
(Hiippala et al, 2016; Pöyhönen et al, 2015), uncovered by panels. In the 
beginning, selected patients have also undergone candidate gene screening 
based on their clinical presentation, with findings in HADHB and DNAJC19 
genes published as clinical reports (Ojala et al, 2012a, 2015b). The above six 
genetic findings from patients belonging to the KidCMP cohort have been 
published separately. In the current screening, we identified disease-causing 
variants in the following genes (Figure 7): PPA2, TAZ, BAG3, NEK8, TBX20, 
TAB2, PTPN11, RAF1, JPH2, CALM1, CACNA1C, TNNC1, TNNI3, ACTC1, 
MYH7, and NRAP. Each disease-causing variant was family-specific in our 
screening. Among all 26 molecular diagnoses in the cohort, 12 (46%) were de 
novo, 9 (34%) recessive, and 5 (20%) dominantly inherited. 
Therefore, de novo variants emerged as a common cause of early-onset 
CMPs, accounting for almost half of genetic diagnoses, with implications for 
family counseling and genetic diagnosis approaches. Our results indicate a 
high genetic heterogeneity in severe childhood cardiomyopathies, with 
family-specific and frequent de novo mutations. We have not identified 
major recessive ancestral mutations enriched in the country, as it is typical 
for other diseases described as Finnish disease heritage (Norio, 2003b). 
 




Figure 7. Heterogeneity of genetic causes in the KidCMP cohort. 
We encountered a high genetic heterogeneity, each family presenting a 
different genetic cause. De novo pathogenic variants were common in the 
cohort, accounting for 46% of diagnoses. The right panel depicts genes 
uncovered in the current screening. Dark blue: a novel clinical presentation. 
Light blue: NRAP novel in childhood CMP. Left panel: genes characterized 
previously from the cohort. 
5.2.3. CONSEQUENCES OF MUTATIONS AT PROTEIN LEVEL 
For an etiological understanding of disease pathogenesis and genotype-
phenotype correlations, it is essential to study the effects of mutations on 
protein structure and function.  
Table 5 summarizes the predicted structural and functional 
consequences of the pathogenic variants identified in our screening, based on 
the current knowledge from literature and our functional assays. 
 
Table 5. Consequences of variants at the protein level.  
Current knowledge of biochemical and predicted functional consequences 



















p.G240R May affect protein stability In silico modeling 






p.P209L The variant occurs in IVP 
motif 2, described to mediate 
the interaction with HSPB8 
and HSPB6 
(Fuchs et al, 2009) 
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p.M224V Likely affects binding in the 




protein kinase Nek8 
p.I215T 
p.R352L 
Unknown. Other pathogenic 
variants altered Hippo 
signaling 
(Frank et al, 2013; 
Grampa et al, 2016) 
TAB2  
TGF-beta-activated 









receptor type 11 
p.Q510E Gain of function. Decreased 
phosphatase activity but also 
decreased autoinhibition, the 
protein adopting easily an 
open, active conformation  
Activity measurements 
and crystal structures 






p.S257L Increased kinase activity and 
enhanced ERK activation 
(Pandit et al, 2007; 
Razzaque et al, 2007) 
p.P261R The variants, p.P261A, 
p.P261L, and p.P261S, show 
increased kinase activity and 
enhanced MAPK1 activation  
(Pandit et al, 2007; 
Razzaque et al, 2007) 




It likely causes loss of function. 
The transmembrane anchor of 
the protein is lost 
Position of the premature 
stop codon. The stability 
of the protein fragment 
was not investigated  
CALM1 
Calmodulin 
p.F142I F142 is adjacent to the fourth 
EF-hand (calcium-binding) 
domain. 
p.F142L reduces the affinity 
for calcium in the C-terminal 
domain and alters the ability 




(Crotti et al, 2013; 






p.G406R Reduced channel inactivation 
resulting in maintained 
depolarizing L-type calcium 
currents 
(Splawski et al, 2005) 
TNNC1  
Troponin C, slow 
skeletal and cardiac 
muscles 
p.A31S Partial activation of a silenced 
calcium-binding domain, EF-
hand 1. Increased affinity for 
calcium 
(Parvatiyar et al, 2012) 
TNNI3 
Troponin I, cardiac 
muscle 
p.V176M Not clear. The change occurs 
in the α-helix 4 of the C-
terminal mobile domain. More 
data is needed regarding the 
interaction with other 
sarcomeric/cytoskeletal 
proteins and about the 
dynamics of the complex 
during the contraction cycle 
Crystal structure of 
cardiac troponin 
(Takeda et al, 2003) 
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Actin, alpha cardiac 
muscle 1 
p.H175R May affect the interaction 
between actin monomers 
Cryo-EM structure of a 
human cytoplasmic 
actomyosin complex 
(von der Ecken et al, 
2016) 
p.Y220H The affected amino acid is 
localized at the edge of the 
ATP-binding pocket and in the 
vicinity of the tropomyosin 
filament 
Cryo-EM structure of a 
human cytoplasmic 
actomyosin complex 











p.S842R Substitution between amino 
acids with different properties 
at the beginning of the rod 
domain: a large positive 
arginine replaces a small 
neutral serine 







p.R925G Amino acids with different 
properties: large arginine 
replaced with small glycine; 
charge transition from + to 0 
in position g of the rod domain 
repeat three 
By analogy with p.E924K, may 








(Gruen and Gautel, 1999) 
p.K1879E Amino acid charge transition 
from + to - in position e of the 









It likely causes loss of function. 
NRAP mRNA harboring the 
premature stop codon is not 
degraded in the patient's heart 
biopsy 
Position of the premature 
stop codon. 
qPCR measurement of 
transcript level 
The stability of the 
protein fragment was not 
determined 
 
5.2.4. MOLECULAR PATHWAYS AFFECTED BY DISEASE GENES 
To establish an accurate prognosis and develop future therapies, it is vital to 
understand the mechanisms involved in disease, how molecular pathways 
are disturbed by mutations, and how they can be modulated with drugs. In 
our screening, the identified genes are involved in mitochondrial metabolism 
(PPA2), cardiolipin maturation (TAZ), protein quality control (BAG3), 
intracellular calcium regulation (JPH2, CALM1, CACNA1C), Ras/MAPK 
signaling (PTPN11, RAF1, TAB2), sarcomeric (MYH7, ACTC1, TNNC1, 





PPA2 defects often manifest as sudden death or as rapidly progressing 
DCM (Guimier et al, 2016, 2016). PPA2 is a mitochondrial protein 
hydrolyzing pyrophosphate to inorganic phosphate, which can be further 
used for ATP synthesis and other processes. We identified two brothers with 
rapidly progressing DCM and compound heterozygous mutations in PPA2. 
Mutations in TAZ typically cause Barth syndrome, which includes CMP. 
TAZ is an acyltransferase responsible for cardiolipin's maturation, the major 
phospholipid in the inner mitochondrial membrane. In our cohort, two 
brothers with DCM presented a previously reported pathogenic variant in 
TAZ (D’Adamo et al, 1997). 
Protein quality control 
Patients with BAG3 mutations, including our patient, present a 
consistent clinical picture of myofibrillar myopathy, cardiomyopathy, with 
rigid spine or neuropathy (Selcen et al, 2009). BAG3 is a co-chaperone of Z-
disk in muscle cells. It is also involved in apoptosis by interacting with BCL2 
and a component of the chaperone-assisted selective autophagy pathway. 
 
 
Figure 8. Pathways affected by disease genes in the KidCMP 
cohort. We uncovered pathogenic variants in sarcomeric and cytoskeletal 
proteins, mitochondrial and other metabolic proteins, developmental, 
MAPK pathways, and calcium signaling proteins. 
 
Development 
NEK8 kinase regulates the primary cilium function on the cell surface 
involved in organ development (Frank et al, 2013). It is also connected to the 
machinery controlling the DNA repair and cell cycle progression (Jackson, 
2013). Our patient manifested with HCM and liver cirrhosis but without 
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kidney involvement, which has been the primary symptom in other patients 
(Rajagopalan et al, 2016). 
TBX20 is a transcription factor essential for heart development (Boogerd 
Cornelis J. et al, 2018), and its mutations manifest with various cardiac 
pathologies (Kirk et al, 2007). Our patient presented LVNC without 
structural heart defects, the typical presentation in other patients. 
Ras/MAPK pathway 
PTPN11 is a component of the Ras/MAPK pathway involved in cell 
growth and differentiation. Mutations in this gene cause Noonan syndrome 
(Takahashi et al, 2005), are typically severe and occur de novo, with a typical 
presentation in our patient. 
RAF1 proto-oncogene contributes to the Ras/MAPK pathway, often 
causes Noonan syndrome with significant HCM (Pandit et al, 2007; 
Razzaque et al, 2007), but sometimes also can lead to isolated DCM 
(Dhandapany et al, 2014). Our patients presented de novo pathogenic 
variants with Noonan phenotype. 
TAB2 is a developmentally regulated gene, part of MAPK pathways. Our 
patient with fatal infantile DCM showed a pathogenic variant causing de 
novo TAB2 haploinsufficiency, previously involved in congenital heart 
disease (Thienpont et al, 2010). 
Calcium signaling 
JPH2 is a component of junctional complexes between the sarcolemma 
and sarcoplasmic reticulum in cardiomyocytes, playing important roles in 
calcium homeostasis and dyad architecture. Mutations in JPH2 associate 
with HCM and DCM (Landstrom et al, 2007; Sabater‐Molina et al, 2016). We 
found a novel homozygous nonsense mutation in JPH2, causing recessive 
DCM. 
Calmodulin is a highly conserved protein of 149 amino acids encoded by 
three genes in the human genome (CALM1, CALM2, and CALM3). This 
redundancy underscores its crucial role in calcium signaling. Our patient was 
a child with LVNC, infantile spasms, and developmental delay, with a de 
novo mutation in CALM1. Another mutation at the same amino acid position 
has been reported to cause non-sustained ventricular tachycardia, markedly 
prolonged QTc interval, and cardiac arrest (Crotti et al, 2013). 
CACNA1C mediates the influx of calcium into cardiomyocytes. Our 
patient was diagnosed with prenatal 2:1 heart block and LVNC. Exon 8 and 
exon 8A of CACNA1C are alternatively spliced, mutually exclusive, and both 
disease-associated. The patient’s mutation resides in exon 8, occurred de 
novo, and was previously associated with Timothy syndrome type 2 





Figure 9. Calcium and MAPK signaling defects in the 
KidCMP cohort. Proteins marked with red presented pathogenic 
variants in our patients. 
 
Sarcomeric and cytoskeletal proteins 
Sarcomeres are contractile units of the muscle, with a highly organized 
protein machinery specialized in the generation of force. The sarcomere's 
primary structural proteins are myosin and actin, which are significant 
components of the thick and thin filaments, respectively (Sequeira et al, 
2014). MYH7 (Myosin-7) is a frequent cause of cardiomyopathies, and we 
identified three novel mutations in this gene, one familial and two de novo. 
On the other hand, thin filament mutations in ACTC1 (Alpha-actin) are also 
well-known causes of cardiomyopathy, with two novel likely mutations in our 
cohort. 
Troponin complex, consisting of troponin C, troponin I, and troponin T, 
regulates the interaction between myosin and actin in response to changes in 
calcium concentration. Troponin C (TNNC1) is the calcium-sensing subunit 
and drives the complex's conformational changes, which allow myosin-actin 
interaction. We identified a previously reported de novo variant in TNNC1 
(Parvatiyar et al, 2012). Troponin I (TNNI3) is the inhibitory component of 
the complex, contributing to tropomyosin maintenance in a position that 
prevents myosin-actin interaction. This gene was found harboring a 
dominantly inherited pathogenic variant in one of the patients. 
NRAP is a cytoskeletal protein involved in anchoring terminal actin 
filaments to the membrane, tension transmission from myofibrils to the 
extracellular matrix, and myofibril assembly. Our study involved for the first 
time NRAP in childhood DCM, previously associated with adult-onset DCM 
(Truszkowska et al, 2017). 
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5.2.5. SUCCESS OF GENETIC SCREENING WITH IMPLICATIONS FOR 
GENETIC DIAGNOSIS OF SEVERE CHILDHOOD 
CARDIOMYOPATHIES 
The overall positive genetic diagnosis rate amounted to 39% in our cohort, 
with 26 patients solved of the total 66 patients. Among the KidCMP’s 66 
patients, 22 (33%) presented a systemic disorder, of which 16 (72%) had an 
age of onset <1 year. A genetic diagnosis was reached in 54% of the systemic 
disease patients and 32% of the isolated cardiomyopathies. Our cohort also 
showed an increase in genetic diagnosis success with later onset: age <1 year 
34% positive DNA diagnosis, 1 to 5 years 38%, 6 to 10 years 60%, 11 to 15 
years 60%. Two-thirds of the infantile (<1 year) DNA findings were explained 
by recessive metabolic genes or de novo variants affecting calcium signaling 
and Ras/MAPK pathways. 
The 39% diagnostic rate is significant, considering that no recurrent 
mutations have been found, but rather family-specific, rare pathogenic 
variants. Moreover, almost half of the identified mutations are de novo 
(emerged during embryogenesis, or mosaic/germline in a parent), which are 
challenging to identify using only the index patient data as it was in our case, 
and would ideally utilize trio screening. Our study brought genetic 
information to over 25 families and a catalog of mutation types in severe 
childhood CMPs in Finland. 
This study used two CMP gene panels and WES, some patients being 
investigated with multiple methods. The concordance of positive findings 
between panels was seven from eight findings (88%) due to a gene not 
covered in both, and between panels and WES was six from 12 findings 
(50%), accounting for genes not covered in panels. Given the high number of 
patients without clarified genetic background, it is evident that many new 
disease genes are still to be uncovered. Together with increased de novo 
findings, our results suggest that WES or WGS of trios is the most suitable 
approach to genetic diagnosis of severe childhood CMPs, especially in 
children <5 years of age. As the diagnosis rate increases in patients >5 years 
at onset, and the panels are continuously incorporating new disease genes, 
they might represent a cost-effective approach for children with later CMP 
onset. 
5.3. TMOD1 IS A NOVEL DISEASE GENE FOR 
CARDIOMYOPATHY (STUDY III) 
5.3.1. CLINICAL PRESENTATION 
In this study, we investigated three patients from two families manifesting 
with childhood-onset CMPs, and who present the same underlying genetic 
cause of disease. 
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Patient 1, daughter of non-consanguineous healthy parents, was 
diagnosed with dilated cardiomyopathy (DCM) and short ventricular 
tachycardia episodes at the age of 12 years. Cardiac magnetic resonance 
imaging (cMRI) showed that both right and left atria were mildly dilated, 
indicating diastolic dysfunction. The right ventricular systolic function was 
normal. The left ventricle was dilated and decreased in systolic function 
(ejection fraction EF 38%). Mild late enhancement in the mid-myocardium 
of the intraventricular septum was observed as a marked dilated 
cardiomyopathy. Ventricular tachycardia responded to oral treatment with 
beta-blockers. Heart failure was further treated with enalapril and diuretics. 
Cardiac function stabilized to the level of mild-to-moderate systolic 
dysfunction during the 10 years follow-up (NYHA 1-2). 
Patient 2 is the daughter of non-consanguineous healthy parents. She 
was referred to the hospital when she was nine years old due to atrial 
enlargement observed on an electrocardiogram (ECG), which was 
incidentally performed as part of a clinical investigation for migraines. cMRI 
demonstrated the dilatation of both atria, as marked diastolic dysfunction. 
Right and left ventricular volumes were normal. Right ventricular systolic 
function was normal, but the left ventricular systolic function was mildly 
decreased (EF 49%). After a two-year follow-up period, the patient began to 
feel weak with dyspnea on effort (NYHA 2). Spiroergometry demonstrated 
decreased oxygen consumption (51%). Warfarin therapy was started to 
prevent atrial thrombus, and she was listed for heart transplantation, 
currently waiting for a transplant. 
Patient 3, the twin brother of patient 2, was initially asymptomatic and 
underwent cardiac ultrasound screening at nine years because of his sister’s 
findings. cMRI demonstrated biatrial enlargement but normal ventricular 
volumes. Right ventricular systolic function was normal, but the left 
ventricular systolic function was mildly decreased on cMRI (EF 45%). After a 
two-year follow-up period, he developed atrial tachycardia and non-
sustained ventricular tachycardia. He became symptomatic with discomfort 
and upper-abdominal pain during exercise. Spiroergometry demonstrated 
decreased oxygen consumption (64%). Beta-blocker and warfarin therapy 
were started, and he underwent ICD implantation for documented non-
sustained ventricular tachycardia. He is currently listed for heart 
transplantation. 
5.3.2. IDENTIFICATION OF TMOD1 VARIANT R189W 
Patient 1 was part of the KidCMP cohort and studied in our lab. Patients 2 
and 3, from the second family, were referred by clinicians to Blueprint 
Genetics for molecular diagnosis. Patients 1 and 2 were first screened with 
gene panels, with negative findings. WES was further used for all three 
patients, and a homozygous missense variant in TMOD1 (Tropomodulin-1, 
NM_003275, NP_003266, c.565C>T, p. R189W) was independently 
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identified in the two families as the most likely cause of cardiomyopathy. The 
variant had a high CADD C-score of 33 and was rated deleterious by SIFT. No 
homozygotes were found in any public databases, and the minor allele 
frequency in Finland is 0.00025 (www.sisuproject.fi). The variant amino 
acid, R189, is highly conserved in species, even in the invertebrates D. 
melanogaster and C. elegans. 
Tmod1 is an actin-binding protein that stabilizes sarcomeric actin 
filaments in cardiomyocytes, playing a crucial role in regulating thin filament 
length and contraction (Gokhin and Fowler, 2011a). 
Two actin isoforms have been described in cardiomyocytes: alpha-
cardiac actin (ACTC1, >80% in the adult heart), part of thin filaments, and 
gamma-cytoplasmic actin (ACTG1), which is a component of the Z-disc, 
surrounds mitochondria, sarcoplasmic reticulum (Gokhin and Fowler, 
2011b), and is also found near sarcolemma (Sequeira et al, 2014). 
In general, F-actin (filamentous-actin) presents two ends: barbed end 
with fast polymerization and pointed end with slow polymerization. In 
cardiomyocytes, CapZ protein caps and anchors to the Z-disc the barbed ends 
(Papa et al, 1999), while Tropomodulin 1 caps the pointed ends in the A-band 
(Weber et al, 1994). 
5.3.3. R189W RESIDES IN ACTIN-BINDING SITE 2 OF TMOD1 AND IS 
PREDICTED TO AFFECT THE LOCAL FOLDING 
Tmod1 functions as a 'leaky' cap at the pointed end of tropomyosin-coated 
actin filaments, allowing for the controlled addition and dissociation of actin 
subunits. Tmod1 harbors two actin- and two tropomyosin-binding sites 
(Figure 10A). The actin-binding site 2, located in the C-terminal region, 
contains a leucine-rich repeat (LRR) domain with four and a half LRR motifs. 
The ascending loops of each LRR motif contact actin. The N- and C- terminal 
caps of the LRR domain, consisting of short alpha-helical regions, shield the 
domain's hydrophobic core from solvent exposure (Figure 10B). 
The homozygous variant p.R189W is localized to the N-terminal cap of 
the leucine-rich domain. The actin-binding sites 1 and 2 of human Tmod1 
were separately crystalized, bound to actin monomers. Figure 10B depicts the 
modeling of patient variant into the crystal structure of the human actin-
binding site 2 of Tmod1 in complex with an actin monomer (PDB id 4PKI) 
(Rao et al, 2014b). The model shows that the amino acid change determines 
the exposure of a hydrophobic residue at the surface of the protein (Figure 
10B). This may influence the alpha-helical folding of the N-terminal cap of 
the LRR domain, its ability to shield the hydrophobic core from the solvent, 





Figure 10. Protein domains of TMOD1, molecular modeling of 
patient variant, and overexpression in U2OS cells. (A) Diagram of 
protein domains (B) Modeling of patient mutation p.Arg189Trp in actin-
binding site 2 of Tmod1 in complex with an actin monomer (C) 
Overexpression of Tmod1wt-GFP and Tmod1R189W-GFP in U2OS cells. 
5.3.4. TMOD1R189W IS PRONE TO FORM AGGREGATES WHEN IT IS 
LINKED TO GFP, BUT NOT WITHOUT 
To test the functional consequences of Tmod1R189W, including possible local 
misfolding suggested by the molecular model, we overexpressed GFP-linked 
wild type and altered protein in U2OS cells. Within one day, Tmod1R189W-
GFP showed a propensity to form aggregates. The aggregates were present in 
different but substantial amounts in the majority of GFP-positive cells. The 
overexpression of Tmod1wt-GFP or GFP-only (empty-vector) did not induce 
this phenotype, indicating that the R189W change underlies this 
presentation. 
The availability of a muscle biopsy from Patient 1 enabled us to analyze 
Tmod1 and Tmod4 levels in skeletal muscle comparing with three control 
samples. Overall, their levels in the patient muscle were within the control 
range, but the controls displayed large variations. This large variation in 
Tmod1 and Tmod4 amounts has been reported for skeletal muscles, probably 
related to their slow and fast fiber composition variability. 
We performed untargeted proteomics from patient skeletal muscle 
biopsy and 5 controls. The most significant upregulated protein in the patient 
was Myosin light chain 4 (MYL4) in untargeted data. Other upregulated 
proteins were: the actin-binding Tropomyosin 1 (TPM1) and Gelsolin (GSN), 
the metabolic proteins Fatty acid-binding protein 4 (FABP4) and Lactate 
dehydrogenase 4 (LDHA), and the stress-response proteins Heat shock factor 
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binding protein 1 (HSPB1) and Alpha-crystallin B chain (CRYAB). The most 
significantly downregulated protein in the patient was Creatine kinase B 
(CKB), a protein involved in energy homeostasis. All the protein changes are 
mirrored at the molecular pathway level by alterations in glycolysis and 
gluconeogenesis, actin cytoskeleton signaling, and other changes indicated 
by IPA (Integrated Pathway Analysis). The proteomics data demonstrates 
that Tmod1 is important in maintaining the structural integrity of the muscle, 
and Tmod1R189W mutation results in the dysregulation of other actin-binding 
proteins. 
5.3.5. EARLY CARDIOMYOCYTE DEVELOPMENT AND TMOD1 R189W 
MUTATION 
We considered that studying the patient's cardiomyocytes will enable us to 
have a more physiologically relevant picture about the mechanism of 
mutation, how it affects the cellular cytoskeleton even before the disorder 
may overtly manifest. Therefore, we engineered induced pluripotent stem 
cells (iPSCs) from patient fibroblasts and further differentiated them to 
cardiomyocytes (CMs) (Burridge et al, 2015). The cells were purified at day 
20 after induction to enrich them in cardiomyocytes and cultured further for 
maturation, which included 15-days culturing in galactose and fatty acids 
medium. The cells were plated at day 45 for immunocytochemistry. The 
patient and control iPSC-CMs were stained to reveal the sarcomeric structure 
and Tmod1 localization. 
 
Figure 11. iPSC-CMs from Patient 1 and Control 1. 
(A) Patient iPSC-CMs have a good sarcomeric development, broadly 
similar to controls. Scale bars: 50 µm and 10 µm (B) Fixation with 
'relaxing buffer'. Tmod1 localizes to the developing M-line in the patient 
and control cells. Scale bars: 25 µm and 5 µm. The white sarcomeric lines 
are drawn in control cells at the same length as in the patient. 
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Cardiac troponin T (cTnT) is a common marker for cardiac differentiation 
and is part of the troponin complex localized along the sarcomeric actin 
filament. Alpha-actinin is a component of the Z-disk, structure that 
delimitates the sarcomeres. Figure 11A shows that patient iPSCs 
differentiated into cardiomyocytes and developed a good sarcomeric 
structure, broadly similar to controls. 
Further, the cells were fixed in relaxing conditions, aiming to open the 
sarcomeres and reveal the structures in their full length, uncontracted. 
However, unlike mature cardiomyocytes, phalloidin staining is much weaker 
along thin filament comparing with the Z-disk area, making the thin filament 
visualization difficult. Although Tmod1 localized mainly to the developing M-
line/A-band at the sarcomeres’ middle, it did not separate in relaxing 
conditions in two rows at the tip of actin filaments, suggesting immature 
structures in both patient and control cells (Figure 11B). 
 
 
Figure 12. Tmod1 localization in iPSC-CMs from Patient 1 and 
Control 1. Asterisk: extra-sarcomeric Tmod1. The white sarcomeric 
lines are drawn in control cells at the same length as in the patient. Scale 
bars: 50 µm and 10 µm. 
 
A fraction of Tmod1 is found in the cytoplasm (Figure 12), and the 
cytoplasmic amount seems in general to be inversely related to the degree of 
sarcomeric development. The heterogeneity of cardiomyocyte differentiation 
makes subtle comparisons challenging. Occasionally, slightly smaller 
sarcomeres in the patient were observed, which could constitute a suggestive 
phenotype (Figure 11B). 
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5.3.6. TMOD1 R189W MUTATION CAUSES ISOLATED 
CARDIOMYOPATHY WITHOUT SKELETAL MUSCLE OR OTHER 
ORGAN INVOLVEMENT 
Tropomodulins (Tmods) are part of a conserved family of proteins, which 
bind tropomyosin-coated actin filaments at their pointed (slow-growing) 
end. Tmods promote actin filament stability by regulating actin monomers' 
addition and dissociation and by enhancing tropomyosin binding. Tmod1 has 
been detected in mammalian striated muscle, red blood cells, ocular lens 
fiber cells, and neurons. From the family members, Tmod2 is neuronal-
specific; Tmod3 is widely expressed, while Tmod4 is restricted to skeletal 
muscle (Yamashiro et al, 2012). Leiomodins (Lmods), part of the same 
family, are structurally and functionally similar to Tmods, but also display 
important sequence and structure differences, ultimately reflected in their 
distinct biochemical activities (Boczkowska et al, 2015). Lmod1 is enriched in 
smooth muscle, while Lmod2 and Lmod3 are expressed in both cardiac and 
skeletal muscles. There is a preferential co-expression of Tmod4-Lmod3 and 
Tmod1-Lmod2, especially in skeletal muscle, explained by a gene regulatory 
network. The current view on these family members is that Lmods nucleate 
actin filaments, which are subsequently capped and stabilized by Tmods 
during sarcomere assembly, turnover, and repair (Fowler and Dominguez, 
2017). 
In skeletal muscle, Tmod1 regulates the capping of thin filament pointed 
end in slow fibers. In fast skeletal muscle, Tmod4 is associated with 
sarcomeric thin filament, while Tmod1 with membrane skeleton and 
costameres. A wide range of compensations between tropomodulin family 
members has been observed in skeletal muscle. Nevertheless, Tmod1 seems 
to be the key isoform controlling thin filament length in skeletal muscle, as 
suggested by Tmod4 knockout mice, as well as by Tmod1 RNAi depletion 
experiments (Gokhin et al, 2015). 
In cardiac muscle, Tmod1 is crucial for thin filament capping. Tmod1 
knockout mice present several abnormalities related to fetal heart 
development, vitelline circulation, and hematopoiesis, with lethality around 
embryonic day ten (Chu et al, 2003; Fritz-Six et al, 2003). Tmod1 expression, 
specifically in the heart, under an alpha-myosin heavy chain promoter, 
rescued lethality and indicated that the knockouts' primary defect is in the 
myocardium (McKeown et al, 2008). More specifically, in the absence of 
Tmod1, the cardiomyocyte myofibrils did not become striated, and gaps in F-
actin staining were not observed (Fritz-Six et al, 2003). The large 
compensations and isoform dynamics described for skeletal muscle do not 
apply to the same extent in the heart. The severe mouse heart phenotype in 
the absence of Tmod1, together with fewer possibilities for compensation 
compared with skeletal muscle, support our finding of partially dysfunctional 
Tmod1 underlying the patients' cardiomyopathies, without the presence of 
skeletal muscle myopathy. 
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Tmod1 also plays an important role in the formation of enucleosome 
during red blood cell maturation, as well as in the architecture of the 
spectrin-based membrane skeleton found in mature erythrocytes and ocular 
lens fiber cells (Nowak et al, 2017; Yamashiro et al, 2012). Tmod1 -/- mouse 
presents spherocytic elliptocytosis (red blood cells surface loss and fragility) 
(Moyer et al, 2010) and morphological abnormalities of lens fiber cells, 
although the latter without strong functional consequences as the mice did 
not develop cataract (Nowak et al, 2009). Our patients did not present 
hematological or ocular symptoms, supporting further the idea that 
Tmod1R189W is a partially functional protein. 
The compensations and dynamics between Tmod and Lmod isoforms, 
and their interaction with tropomyosin ultimately determine thin filament 
length, actomyosin cross-bridge formation, and force generation. The K15N 
mutation in the TPM1 (Tropomyosin 1) has been described in familial DCM 
(Hershberger et al, 2010) and was found to negatively affect the binding 
properties of Tmod1 and Lmod2 with tropomyosin-coated actin filaments 
and pointed end dynamics (Colpan et al, 2016, 2017), highlighting once more 
the close relationship between thin filament proteins. Furthermore, an 
LMOD2 homozygous nonsense mutation was recently described to cause 
neonatal DCM (Ahrens-Nicklas et al, 2019). In this framework, we can 
understand that mutations in any of these thin filament-associated proteins 
can alter F-actin dynamics and may present in the form of CMP, skeletal 
muscle myopathy, or in the form of compensatory changes through related 
proteins. 
Although the exact mechanism by which our patients’ variant affects the 
capping at the pointed end remains still open, mutants of the C-terminal 
region containing the LRR domain exhibited reduced capping activity (Rao et 
al, 2014b). 
Based on the high conservation of the variant amino acid in species, 
absence of homozygotes in population databases, structural modification 
predicted to affect the local folding, and the propensity to form aggregates 
when linked with GFP, we judged TMOD1 to be a novel gene causing isolated 
childhood CMP, without skeletal muscle or other organ involvement. 
Given the crucial role of actin in cellular architecture and contractility 
plus its interaction with many proteins involved in assembly/disassembly, 
anchoring, capping, and turnover of the filaments, it is not surprising that 
mutations in actin-binding partners cause human disorders. In this study, we 
add Tmod1, a regulator of actin filament length in cardiomyocytes, to the 
genetic causes of CMPs that originate from thin filament dysfunction. 
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6. CONCLUSIONS AND FUTURE 
PROSPECTS 
The studies presented in this thesis are based on genetic discoveries made 
with NGS. Selected findings were further investigated by functional assays, 
which extended to patient-derived iPSC-CMs. 
Our first study used WES to identify a novel mutation in HIKESHI, 
causing hypomyelinating leukoencephalopathy accompanied by severe 
deterioration of symptoms during a febrile episode and a malignant ovarian 
tumor. Previously, six patients from three families of AJ ancestry were 
described with a founder disease-causing variant in HIKESHI. The 
involvement of Hikeshi in disease has linked its function of heat shock-
induced transport of HSP70s into the nucleus with leukoencephalopathy 
(Edvardson et al, 2016). We further showed that Hikeshi disease 
mechanisms involve both nuclear chaperone and ER functions. HSP70s play 
crucial roles in preventing protein aggregation in the CNS, but they also 
contribute to the disaggregation of formed amyloid fibrils (Wentink et al, 
2020). Consequently, the role of Hikeshi in age-associated 
neurodegenerative disorders remains to be unraveled. 
Valuable insights into the critical pathways required for myelin 
formation and maintenance can be drawn from the genetics of 
leukoencephalopathies and leukodystrophies (Stadelmann et al, 2019). 
Besides Hikeshi, other white matter disorders with significant deterioration 
following febrile illnesses are caused by mutations in eIF2B complex required 
for protein synthesis [vanishing white matter disorder, reviewed in (Moon 
and Parker, 2018; Pavitt, 2018)], and nucleoporin NUP214 [acute febrile 
encephalopathy, (Fichtman et al, 2019)]. These genetic causes strengthen the 
idea that heat shock response is a bona fide pathogenic mechanism and 
highlight its connections with protein homeostasis and with cytoplasmic-
nuclear transport. 
In this context, further studies should aim to characterize in detail the 
Hikeshi-mediated HSP70s nuclear import pathway in myelin disorders, the 
relationship between ER redox state and the heat shock response, and their 
possible connection with unfolded protein response (Clayton and Popko, 
2016; Lin and Stone, 2020). 
Our second project used NGS targeted sequencing panels and WES for 
the genetic characterization of severe childhood cardiomyopathies in a 
countrywide cohort. The genetic basis of early manifesting CMPs has not 
been systematically characterized in Finland. We expected to identify major 
recessive ancestral mutations enriched in the country, as it is typical for other 
monogenic disorders (Norio, 2003c). In adult cardiomyopathy patients from 
Finland, founder heterozygous mutations have been identified in the 
sarcomeric genes MYBPC3, MYH7, and TPM1 (Jääskeläinen et al, 2019), as 
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well as in JPH2 involved in calcium handling (Koskenvuo et al, 2018). This 
was, however, not the case in our study. Instead, we found a remarkably 
heterogeneous genetic background, each family presenting a different 
mutation, almost half of them occurring de novo. A positive genetic diagnosis 
was reached in 39% of patients. The significant number of patients that 
remained unresolved indicates that new disease genes are still to be 
discovered and point to the importance of whole-genome analysis. Whether 
those gene defects allow enrichment in the population remains to be seen. 
The high genetic heterogeneity observed in early-onset cardiomyopathies 
underscores the vital importance of many cellular processes and the 
coordinated action of a myriad of proteins to drive efficient and sustained 
heart muscle contraction. NGS tools enable a better understanding of 
cardiomyopathies' genetic causes, which can open possibilities for 
interventions and offer individualized treatment choices, especially 
important in major invasive procedures such as cardiac transplants. 
Our findings have important implications for a global understanding of 
childhood cardiomyopathy genetics. They indicate the benefits of NGS as a 
first-line diagnosis in children considered for a heart transplant, and they 
trace the molecular pathways affected by disease genes. KidCMP cohort 
demonstrated the primary progressive nature of specific gene defects, 
whereas others spontaneously stabilized, despite all manifesting as severe 
disorders, and most were considered for heart transplantation. 
Consequently, genotype information provides tools for robust assessment of 
the natural history of the disease, enabling individualized care and 
prioritization of patients for cardiac transplantation. 
To illustrate this point, the cardiac findings in mitochondrial 
cardiomyopathies (TAZ, MRPL44, and DNAJC19) stabilized spontaneously 
in the minority of patients who survived through the early years (Carroll et al, 
2013; D’Adamo et al, 1997; Ojala et al, 2012b). A similar finding in our lab 
was for TSFM defects, causing mitochondrial CMP with neurological 
involvement (Ahola et al, 2014). The potential of spontaneous partial 
recovery of CMP emphasizes an intensive, conservative treatment strategy to 
support these patients' heart function through their infantile years. 
In our cohort, 60% of patients are still without a molecular diagnosis. 
There are several factors to consider in our attempts to uncover the 'missing 
heritability' in rare disorders. First, rare disorders may display both 
phenotypic heterogeneity (strikingly different phenotypes associated with 
different variants in the same gene) and genetic heterogeneity (variation in 
distinct genes leading to similar phenotypes) (Wright et al, 2018). 
Considering this aspect may be crucial for a successful approach to diagnosis. 
The success may also depend on the type of test used, WGS trio sequencing 
proving superior in the diagnostic rate and the time to reach the diagnosis 
(Fitzgerald et al, 2015). 
Although NGS allowed 'reverse phenotyping' in many patients, deep 
phenotyping becomes essential for diagnosing difficult cases. The concept of 
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deep phenotyping includes the use of terms defined in the Human Phenotype 
Ontology database (Köhler et al, 2017; Robinson and Mundlos, 2010), terms 
representing a standardized description of abnormalities associated with 
disorders (Köhler et al, 2019). Matchmaking tools, such as GeneMatcher 
(Sobreira et al, 2015), PhenomeCentral (Buske et al, 2015), and 
MatchmakerExchange (Philippakis et al, 2015), also help in matching 
patients with similar rare phenotypes and with the same candidate gene, 
contributing to positive findings. 
Another consideration relates to the mutation spectrum. Presently, SNVs 
are the type of variation most accurately represented in public databases. 
There is a need for better methods to detect, compile, and compare indels 
and SVs across populations. Third-generation sequencing, coupled with 
bioinformatic advancements, can overcome these challenges. To accurately 
discover SVs, including repeat expansions, there is a need to develop novel 
bioinformatic tools (Antaki et al, 2018; Jakubosky et al, 2020). In this 
direction, machine-learning algorithms are created to merge calls from 
different SV-calling platforms (Becker et al, 2018). Another novel tool is 
Expansion Hunter, which uses PCR-free WGS short reads to identify long 
repeat expansions (Dolzhenko et al, 2017). 
Somatic variants are more often discovered in patients resistant to 
conventional NGS-based diagnostic approaches. Increasing the depth of 
sequencing and choosing the affected tissue as starting material whenever 
possible will increase the detection of this subtype of variation.  
Moreover, multilocus genetic inheritance can be considered in patients 
difficult to diagnose. This situation may include atypical clinical presentation 
due to two or more overlapping genetic conditions, disorders with digenic 
inheritance (DIDA database of digenic disorders, http://dida.ibsquare.be/) 
(Gazzo et al, 2016), and oligogenic inheritance that may occur even in 
disorders classically considered monogenic, such as LongQT syndrome. 
Genetic modifiers may alleviate or amplify the primary causative variant 
effect, but their influence is difficult to evaluate in small cohorts. Large-scale 
projects that combine genotype and phenotype information should shed light 
on modifiers, penetrance, and expressivity in rare disorders. 
Furthermore, unknown causative genes and variants in noncoding 
regions with unknown effects are important causes of missing diagnoses. 
Assigning function to poorly characterized protein- and RNA-genes, as well 
as to functional noncoding elements of the genome, will improve the 
interpretation of variants in the near future (Ward and Kellis, 2012). 
The reference genome and variome resources are key for the accurate 
discovery of disease variants in rare disorders. The reference genome 
GRCh38 is of high quality in most regards (Schneider et al, 2017). However, 
it still has gaps (Miga, 2015) and errors at repetitive and structurally diverse 
regions (Ameur et al, 2018), as well as many ultra-rare variants (Magi et al, 
2015). Even more important for genetic studies, the reference genome does 
not capture the diversity of our collective human genome of eight billion 
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people because it is a composition of sequences that originate from only a 
small number of individuals. The principle of capturing the diversity is of 
high importance because if a sequence is not represented in the reference, or 
if it is too divergent from the reference, most algorithms will not detect it. 
Ongoing efforts are undertaken to append alternative loci to the reference 
(Church et al, 2015), but presently most tools and pipelines do not make use 
of them. A future pan-genome resource has the ambition to capture all 
relatively common sequences and alleles across human populations, which 
will be represented as a graph-based data structure. Many initiatives in 
recent years aim to build reference variant databases for different 
populations. A few examples include the Genome Russia project (Oleksyk et 
al, 2015a, 2015b), the Ashkenazi-Jewish reference panel (Lencz et al, 2018), 
and the Silent Genomes Project (www.bcchr.ca/silent-genomes-project) of 
the Canadian indigenous population. 
Incorporating multi-omics layers (from affected tissue or blood) can also 
bring valuable information. For example, RNA sequencing information 
enables detecting biased expression levels or splicing effects that are difficult 
to predict from WES or WGS data (Deelen et al, 2019). Further, proteomics 
and metabolomics data will shape a better understanding of the pathogenic 
processes, which can help to identify the responsible gene. Altogether, these 
combined approaches will promote the discovery of the 'missing heritability' 
in rare disorders. 
Our third project identified TMOD1 as a novel genetic cause for 
childhood cardiomyopathies in three patients from two unrelated families, by 
using WES. Tmod1 binds and stabilizes tropomyosin-coated actin filaments 
at their pointed end (Weber et al, 1994), regulating the length and stability of 
the thin filament in cardiomyocytes. 
Actin is the most abundant protein in mammalian cells, and the 
importance of actin-driven processes highlights that the control of actin 
filament dynamics is crucial (Svitkina, 2018). This is also suggested by 
compensatory mechanisms shown in different models where Tmod family 
members have been altered. The manifestation age of TMOD1 defect was 9-
12 years, suggesting that a less severe mutation can have a later onset and 
indicating TMOD1 screening also in adult patients. Future studies should 
establish the biochemical properties of the Tmod1R189W pathogenic variant, 
how it affects the length of thin filaments in mature cardiomyocytes and the 
generation of force. 
We used iPSC-CM disease modeling, with only suggestive findings in our 
patient's cells. This brings into the spotlight a discussion regarding the 
challenges of iPSC-based disease modeling and of strategies to improve 
cardiomyocyte differentiation outcomes (Parrotta et al, 2019). One challenge 
relates to adequate controls, as iPSCs exhibit a large heterogeneity upon 
differentiation (Mirauta et al, 2020) that can confound interpretation. 
Isogenic cell lines created by CRISPR editing approaches circumvent this 
issue by providing a homogeneous genetic background (DeBoever et al, 2017; 
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Kilpinen et al, 2017). However, editing strategies introduce the possibility of 
off-target effects and the need for NGS screening of the cell lines. 
Furthermore, stringent criteria remain to be defined for completely 
reprogrammed iPSC lines, as some retain epigenetic memory, which 
influences their capacity to differentiate. 
Modeling late-onset disorders has been less successful due to recurrent 
immaturity of derived cells and the lack of native environmental cues (Doss 
and Sachinidis, 2019). Another confounding effect is the heterogeneous 
mixture of cells obtained upon differentiation. In cardiomyocyte 
differentiation, atrial, ventricular, and nodal subtypes co-occur in the same 
culture, together with other types of cells (Duelen and Sampaolesi, 2017). In 
our patients with TMOD1 mutation, the heart atria were especially affected, 
suggesting that the selection of atrial cardiomyocytes could constitute a 
future strategy for dissecting the Tmod1 disease mechanism in iPSC-CMs. 
Moreover, iPSCs acquire genomic instability (Merkle et al, 2017) with 
increased passage numbers, manifesting as chromosomal abnormalities, 
CNVs, and loss of heterozygosity (Henry et al, 2019; Steichen et al, 2019). 
The genome integrity maintenance is especially relevant for iPSC-CMs 
because a good differentiation requires a higher passage (Burridge et al, 
2015). Engineering cells with one of the 'suicide gene therapy' approaches 
could represent a future solution to eliminate abnormal or unwanted cells 
from a mixed culture. An example is the caspase 9 suicide system, inducible 
by the AP1903 drug, and leading to rapid apoptosis of cells expressing the 
construct (Zhou et al, 2015). 
As efforts to decipher the genetic basis of rare disorders progress towards 
completion, functional studies remain important to understand the 
mechanisms by which disruptive variation leads to disease phenotypes. This 
underlines the importance of tools to model disorders, like iPSC-CMs, with 
isogenic controls obtained by editing technologies. From the perspective of 
personalized medicine, we envisage that genotype-phenotype correlations 
will provide a framework to evaluate disease progression and will enable 
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